POPULARITY
11 episodes with healio
11 episodes with healio
8 episodes with healio
10 episodes with healio
5 episodes with healio
3 episodes with healio
4 episodes with healio
3 episodes with healio
2 episodes with healio
In this episode John A. Hovanesian, MD, FACS, and Jim Mazzo are live from SightLine at the ASCRS meeting with guests Nicole R. Fram, MD, Kerry D. Solomon, MD, Vance Thompson, MD, and Steve Speares. Welcome to the Eyeluminaries podcast 00:02 Review of episode 32 00:55 Intro of Nicole Fram, MD 01:16 Tell us why the MAHRVELS team is likely to be the leading fundraisers and why you picked your character for the team to portray (The Scarlet Witch)? 02:24 Meeting about complications from cataract surgery, what do you think is the next big phase on how we're going to handle complications with technology? 04:05 Psychology of managing patients/conveying care 05:42 What advice do you give to people who are starting their career? 06:50 Intro of Kerry Solomon, MD 09:30 What do we often get wrong with cataract surgery and what do we often get right? 10:25 How do you stay an entrepreneur and a leading physician? 11:55 What is Operation Sight? How did you create it? 14:19 Where will keratorefractive surgery and lens-based surgery be in 5 or 10 years? 18:30 Intro of Vance Thompson, MD 21:24 What's it like to be ASCRS president? 21:59 What is BRiCS and why is it important? 23:54 You've created a culture; can you talk about that culture you've created at your institute? 29:30 Tell us about your winery! 33:28 Intro of Steve Speares 36:45 ASCRS just wrapped up. Your idea of creating a SightLine with a business approach, what did you do and what was the idea? 38:00 As you look back and you look ahead, what changes do you hope to make? What do you hope your legacy will be at ACSRS? 40:57 Can you expand more on how Washington, DC and Trump administration will impact your society/group? 44:19 Richard Lindstrom in ASCRS hall of fame, tell us your own perspective and a good story 46:29 Preview of episode 34 52:09 Give us your feedback 52:40 Thanks for listening 52:56 Nicole Fram, MD, is an adjunct assistant professor at the John A. Moran Eye Institute at the University of Utah. She is also the secretary for ASCRS, is a member of the Cataract Clinical Committee, and leads the Ophthalmology Quicksand Chronicles podcast with co-host Elizabeth Yeu, MD. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Kerry Solomon, MD, is internationally renowned for LASIK and refractive cataract surgery. He is the co-founder of Operation Sight. He is the former chairman of the ASCRS FDA Committee. Steve Speares, MD, is the executive director at ASCRS. Vance Thompson, MD, is the founder of Vance Thompson Vision and director of refractive surgery in Sioux Falls, SD. He serves as a professor of ophthalmology at the Sanford School of Medicine at the University of South Dakota. Thompson is the immediate past president of ASCRS. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Fram, Speares, Solomon, and Thompson at the time of publication.
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news from Washington with guest Mark Leahey. Welcome to the Eyeluminaries podcast :02 Review of episode 31 :40 BVI Medical names a new CCO 2:20 GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions 5:42 Tenpoint submits new drug application for presbyopia combination therapy 7:33 Alcon acquires majority stake in Aurion Biotech 10:29 FDA approves Encelto for macular telangiectasia type 2 14:50 Intro of Mark Leahey 17:28 There is a lot of attention on the HHS restructuring. What are your insights into what has happened to date, and what could happen in the future? 20:10 What do you think about the leadership? 23:44 Let's talk about sustainability. Tell us about the medical device industry's collective interest and challenges in regard to moving toward environmentally sustainable initiatives. 24:59 Let's talk about leadership: Dr. Marty Makary and Dr. Oz. 27:53 Tariffs are an evolving subject. What is the impact on the medical community? What is your impression on how these will affect us in the short term and long term? 33:20 Preview of episode 33 39:27 Give us your feedback 40:23 Team Mah-rvel: the Party for a Purpose 40:41 Thanks 40:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO for the Medical Device Manufacturers Association (MDMA). Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Leahey.
Send us a textAbout Dr. Jade CoatsDr. Jade Coats is a 2016 of the Southern College of Optometry in Memphis, TN, and since graduation has worked in an OD/MD cataract/refractive surgery practice (McDonald Eye Associates, Rogers, Arkansas) in which she dedicates the majority of her clinical practice to ocular disease, comprehensive eye care, and contact lenses. Honored as a Contact Lens Institute Visionary in both 2023 and 2024, Dr. Coats is also a board member for Women in Optometry, the Intrepid Eye Society, and YoungODsConnect. She is an active member of the American Optometric Association as a graduate of the AOA Leadership Institute 1.0 and 2.0 programs, and was also elected in 2024 to serve as a Director on the Arkansas Optometric Association board. In addition to her clinical work, Dr. Coats serves on the advisory board and/or as a speaker for over ten pharmaceutical companies and is an editorial board member for numerous publications. She also regularly contributes to leading industry publications, with her work appearing in Advanced Ocular Care, Primary Care Ocular News, Healio, Review of Optometry, Optometry Times, Optometric Management, and Modern Optometry, to name a few. Receiving several local, state, and national awards for her dedication to philanthropy and her profession, Dr. Coats has also recently been honored as one of NWA Celebrate Arkansas Magazine's 'Ones to Watch' in 2023. https://digitaleditions.walsworth.com/publication/?m=9337&i=805683&p=80&ver=html5. In Dr. Coats' spare time, she serves on the Board of Directors for Hope Cancer Resources and Circle of Life Hospice in Northwest Arkansas and has established a non-profit organization known as “Caton's Cubs” that works in coordination with Arkansas Hospice. You may find Dr. Coats enjoys calling the Hogs at Razorback games, scuba diving, traveling the world, or volunteering in her community. (Or, hanging out with her husband, Jeff Coats, who is also an Optometrist!)
Send us a textAbout Dr. Jade CoatsDr. Jade Coats is a 2016 of the Southern College of Optometry in Memphis, TN, and since graduation has worked in an OD/MD cataract/refractive surgery practice (McDonald Eye Associates, Rogers, Arkansas) in which she dedicates the majority of her clinical practice to ocular disease, comprehensive eye care, and contact lenses. Honored as a Contact Lens Institute Visionary in both 2023 and 2024, Dr. Coats is also a board member for Women in Optometry, the Intrepid Eye Society, and YoungODsConnect. She is an active member of the American Optometric Association as a graduate of the AOA Leadership Institute 1.0 and 2.0 programs, and was also elected in 2024 to serve as a Director on the Arkansas Optometric Association board. In addition to her clinical work, Dr. Coats serves on the advisory board and/or as a speaker for over ten pharmaceutical companies and is an editorial board member for numerous publications. She also regularly contributes to leading industry publications, with her work appearing in Advanced Ocular Care, Primary Care Ocular News, Healio, Review of Optometry, Optometry Times, Optometric Management, and Modern Optometry, to name a few. Receiving several local, state, and national awards for her dedication to philanthropy and her profession, Dr. Coats has also recently been honored as one of NWA Celebrate Arkansas Magazine's 'Ones to Watch' in 2023. https://digitaleditions.walsworth.com/publication/?m=9337&i=805683&p=80&ver=html5. In Dr. Coats' spare time, she serves on the Board of Directors for Hope Cancer Resources and Circle of Life Hospice in Northwest Arkansas and has established a non-profit organization known as “Caton's Cubs” that works in coordination with Arkansas Hospice. You may find Dr. Coats enjoys calling the Hogs at Razorback games, scuba diving, traveling the world, or volunteering in her community. (Or, hanging out with her husband, Jeff Coats, who is also an Optometrist!)
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Hawaiian Eye meeting with guests Paul Singh, MD, Candy Simerson, Jeffrey Goldberg, MD, PhD, and Roger Goldberg, MD, MBA. Welcome to the Eyeluminaries podcast :02 Review of episode 30 3:23 Intro of Paul Singh, MD 3:40 What are the future trends in glaucoma you're most excited about? 5:10 What challenges do you see in running your practice that didn't exist in your dad's day? 8:36 You've got a great medical office, a very busy consulting and research practice, you play in a band and you have a young family. What advice would you give others in keeping it all in balance? 12:09 Besides your dad and the two of us, who do you look up to in eye care? 14:45 Singh sings a Funkadesi song 18:16 Intro of Candy Simerson 20:36 When you come into a new practice to consult, what are the most common areas you see where improvement can be made? 21:41 What about the finances? What areas in finances do you see where improvement can be made? 24:27 In your many years in ophthalmology, what are the biggest challenges you've experienced? 26:10 What type of practice should consider a sale to private equity? What type of practice should not? 29:34 What advice would you give a company representative who wants to win business from a big ophthalmology practice? 32:29 Intro of the Goldbergs 36:25 Jeff Goldberg, MD, PhD 36:50 Roger Goldberg, MD, MBA 37:21 Jeff, why glaucoma instead of retina? 38:43 Roger, why retina instead of glaucoma? 39:37 Mazzo discusses neuroprotection in retina and glaucoma. 41:14 What is entrepreneurship like today? What's your advice? What is challenging and what is positive? 43:10 Mazzo discusses being realistic about innovations. 48:30 What is private practice like today? 49:31 How do cornea specialists better understand glaucoma specialists? 53:05 How do cornea specialists better understand retina specialists? 54:13 Tell us about emmecell. 55:50 Preview of episode 32 59:19 Give us your feedback 1:00:18 Thanks 1:00:30 Jeffrey Goldberg, MD, PhD, is professor and chair of ophthalmology at the Byers Eye Institute at Stanford University and a member of the National Academy of Medicine. Roger Goldberg, MD, MBA, board certified by the American Board of Ophthalmology and is an active member of the American Society of Retinal Specialists, the Retina Society and the American Academy of Ophthalmology. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Candy Simerson is the senior vice president of practice operations at Vision Integrated Partners. I. Paul Singh, MD, is the president of The Eye Centers of Racine & Kenosha, Ltd., founded in 1981 by his father, Dr. Kanwar A. Singh. He is a founding member of the band, Funkadesi, a mix of Indo-Afro-Caribbean style music. The band tours the world spreading the message “one family, many children.” We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for the Goldbergs, Simerson and Singh at the time of publication.
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Steven Dell, MD, about his career and the creation of markets in the field of ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 29 1:28 Bausch + Lomb acquires Elios Vision 2:07 ImprimisRx awarded $34.9 million in trademark infringement suit against OSRX 5:00 Study of atropine-based myopia treatment fails to meet primary efficacy endpoint 7:31 Intro of Steven Dell, MD 11:20 You have created markets with new technologies and companies. Can that continue in today's market? 13:28 Dell discusses presbyopia market development. 14:11 You created a questionnaire that you used in your practice, which has become known as the Dell Questionnaire. What do we need to do better in treating our cataract patients? 16:20 What technologies are going to be the most important in the future? 20:24 What has changed in your office environment, i.e., the role of ODs, admin, staff? 22:00 Dell discusses Lindstrom's Integrated Eye Care Delivery Model. 23:08 What advice would you give a younger Steven Dell? 27:16 Neurotech Pharmaceuticals announced that chief commercial officer Scott Hunter died on Dec. 3. 33:06 Give us your feedback 34:43 Thanks 34:51 Steven J. Dell, MD, is a board-certified ophthalmologist in Austin and the Medical Director of Dell Laser Consultants. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Dell at the time of publication.
In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the ASH Annual Meeting and Exhibition, as well as Healio's top headlines from the meeting. Gwen L. Nichols, MD, reviews a panel discussion on how hematologists and oncologists can best address patients' concerns as AI's role in medicine invariably expands. :24 Thomas G. Knight, MD, addresses financial toxicity for people with blood cancer. 6:29 Charles S. Abrams, MD, discusses results of the HIBISCUS trial and its implications for vaso-occlusive events. 16:30 Read the full coverage here: AI in hematology: ‘The good, the bad and the ugly' Mitigating financial toxicity 'better than any drug' for people with cancer Etavopivat could offer ‘great benefit' in sickle cell disease ASH recognizes Judith Kleinerman, MD, with Exemplary Service Award GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no financial disclosures. Abrams reports he is chair of the ASH Research Collaborative's Sickle Cell Disease Clinical Trials Network Oversight Committee. Knight reports no relevant financial disclosures. Nichols reports no relevant financial disclosures.
In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the 2024 World Conference on Lung Cancer, as well as Healio's top headlines from the meeting. With insights from Benjamin P. Levy, MD, and top headlines from the conference, Meeting Mic is your on-the-go source for highlights, pearls, and perspectives across all specialties. Benjamin P. Levy, MD, discusses key takeaways from the meeting. 0:49 Read the full coverage here: Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard' Source: Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Perioperative nivolumab improves outcomes in resectable NSCLC Source: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Despite progress, barriers to lung cancer biomarker testing persist Source: Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Levy at the time of posting.
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Tom Mitro about his career and impact in ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 26 :58 FDA grants fast track designation to brepocitinib for noninfectious uveitis 1:42 I. Howard Fine, MD, esteemed ophthalmologist, dies 3:54 First subjects dosed in phase 3 trial of phentolamine ophthalmic solution for presbyopia 5:48 LENZ Therapeutics submits NDA for drops to treat presbyopia 7:57 Intro of Tom Mitro 10:40 Tell us about your journey in ophthalmology 12:38 Tell us about the new dry eye drug from Signal 12. 15:53 How much sensation is on the forehead if the drug is well tolerated? 24:13 What are your thoughts on the current ophthalmology market? 26:01 Tell us a funny story about Jim Mazzo and about John Hovanesian. 28:51 Preview of episode 29 33:25 Give us your feedback 34:34 Thanks 34:50 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Tom Mitro is the president and chief operating officer for Aerie Pharmaceuticals. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Mitro at the time of publication.
On this special edition episode, Shikha Jain, MD, with Physicianary's Hansa Bhargava, MD, and Mend the Gap's Dagny Zhu, MD, discuss the evolution of empowering yourself and others and advocacy with a panel of guests. • Intro 1:01 • What does it mean to empower women in medicine, and what are the ways that we can really empower others to achieve the things that they may not see for themselves? 2:39 • What are some ways in which you have empowered or hope to empower women in medicine? Are there tips or skills that have worked well? 5:43 • How have you been empowered by others, or have helped others find their voices? 8:38 • Do you agree that the conversation is changing toward a cultural shift in empowerment for women in health care? 13:53 • What are some challenges facing advocacy and empowerment? What do you do when your advocacy work is not being received or it is a struggle to speak up for someone? 18:40 • Emphasizing the importance of communication in advocacy work. 24:00 • Intro to Physicianary's part 3 on physician burnout and work-life balance. 24:16 • Thanks for listening 25:00 Vineet Arora, MD, MAPP (NAM), is a Herbert T. Abelson professor of medicine, vice dean of education in the biological sciences division and dean for medical education at the University of Chicago Pritzker School of Medicine. She is also an elected member of the National Academy of Medicine. She is a founding member of the 501c3 Women of Impact and advisor to the Women in Medicine Summit. Jennifer Bepple, MD, MMCi, is a double board-certified physician in urology and informatics. She is a member of the American Telemedicine Association, American Urologic Association and American Medical Informatics Association and holds a certification from the American Board of Telehealth and the American Board of AI in Medicine. Hansa Bhargava, MD, is Healio's chief clinical strategy and innovation officer. Listen to her Healio podcast, Physicianary. Shikha Jain, MD, FACP, is a board-certified hematology and oncology physician. She is a tenured associate professor of medicine in the division of hematology and oncology, the director of communication strategies in medicine and the associate director of oncology communication & digital innovation at the University of Illinois Cancer Center in Chicago. Mara Schenker, MD, FACS, FAOA, is an orthopedic trauma surgeon at Grady Memorial Hospital. She is double board certified in orthopedic surgery and clinical informatics. She serves as the chief of orthopedics and associate chief medical information officer. She is an associate professor of orthopedics at Emory University School of Medicine. She serves on multiple boards for medical and digital technology advisory and sits on major national committees for the American Academy of Orthopaedic Surgeons, AAMC, American College of Surgeons and the Orthopaedic Trauma Association. Dagny Zhu, MD, is a cornea, cataract and refractive surgeon and medical director and partner at NVISION Eye Centers in Rowland Heights, CA. She can be reached on X @DZEyeMD. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: The hosts and guest report no relevant financial disclosures.
On this special edition episode, Dagny Zhu, MD, with Oncology Overdrive's Shikha Jain, MD, and Physicianary's Hansa Bhargava, MD, discuss leadership in medicine and the importance of mentorship with a panel of guests. Intro 0:28 Meet the panel 2:00 Vineet Arora, MD 2:12 Jennifer Bepple, MD 2:29 Mara Schenker, MD, FACS 2:55 In this episode 3:21 How did you become the leader that you are today? And what is your advice for young physicians who want to find themselves in your position one day? 3:27 Were you always “leadership material” or was it something you developed over time? 10:26 How has mentorship improved your outlook on your career? And what is your advice on finding a good mentor? 12:33 What are some quick, easy tips to finding a mentor? 23:07 Thanks 25:38 Join us for part two on Oncology Overdrive 25:41 Vineet Arora, MD, MAPP (NAM), is a Herbert T. Abelson professor of medicine, vice dean of education in the biological sciences division and dean for medical education at the University of Chicago Pritzker School of Medicine. She is also an elected member of the National Academy of Medicine. She is a founding member of the 501c3 Women of Impact and advisor to the Women in Medicine Summit. Jennifer Bepple, MD, MMCi, is a double board-certified physician in urology and informatics. She is a member of the American Telemedicine Association, American Urologic Association and American Medical Informatics Association and holds a certification from the American Board of Telehealth and the American Board of AI in Medicine. Hansa Bhargava, MD, is Healio's chief clinical strategy and innovation officer. Listen to her Healio podcast, Physicianary. Shikha Jain, MD, FACP, is a board-certified hematology and oncology physician. She is a tenured associate professor of medicine in the division of hematology and oncology, the director of communication strategies in medicine and the associate director of oncology communication & digital innovation at the University of Illinois Cancer Center in Chicago. Listen to her Healio podcast, Oncology Overdrive. Mara Schenker, MD, FACS, FAOA, is an orthopedic trauma surgeon at Grady Memorial Hospital. She is double board certified in orthopedic surgery and clinical informatics. She serves as the chief of orthopedics and associate chief medical information officer. She is an associate professor of orthopedics at Emory University School of Medicine. She serves on multiple boards for medical and digital technology advisory and sits on major national committees for the American Academy of Orthopaedic Surgeons, AAMC, American College of Surgeons and the Orthopaedic Trauma Association. Dagny Zhu, MD, is a cornea, cataract and refractive surgeon and medical director and partner at NVISION Eye Centers in Rowland Heights, CA. She can be reached on X (formerly Twitter) @DZEyeMD. We'd love to hear from you! Send your comments/questions to podcast@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The hosts and guest report no relevant financial disclosures.
Dr. Greg talks with Emily L. Weis, MD, MS, with the University of Rochester, who recently was featured in an article in Healio about how physicians are dealing with a rise in difficult patient encounters and what may be behind the uptick.
This week we had such an interesting conversation with Dr. Erica Barnell. Dr. Barnell is the Co-Founder and Chief Medical and Science officer for Geneoscopy, Inc! Geneoscopy is a life-sciences start-up company that leverages eukaryotic biomarkers to non-invasively diagnose, monitor, and treat gastrointestinal disease. The idea for Geneoscopy was conceived during Dr. Barnell's first clinical rotation while earning her MD/Ph.D. at Washington University School of Medicine in St. Louis. Specifically, Erica encountered a woman with Stage IV colorectal cancer (CRC) who had never undergone a colonoscopy, citing the inconvenience and burden of attending a traditional colonoscopy as key barriers. Dr. Barnell developed an easy non-invasive stool test to screen for colon cancer and she is now expanding it to the IBD space. She and her team are working to be able to use this RNA screening tool to allow for better prediction of treatment outcomes, disease monitoring and more. We talked to her about developing her initial test, going through the FDA approval process, and then developing a company while still finishing her MD/PhD. We also talked to her about starting a company with her brother and all of the many life changes she went through during it's initial stage as well. We discussed RNA technology and she gave us a quick lesson on it, and finally we discussed her participation in the Crohn's & Colitis Foundation's IBD Innovate Conference earlier this year and how it helped her premier her product to the IBD space and to explore possible partnerships and funding opportunities. Robin and I are big geeks for research and innovation and this conversation with Erica was so fun. Please keep in mind that the views and opinions expressed in this program are those of the speakers and should not be considered medical or legal advice. Please consult with your healthcare team on any changes to your disease, diet, or treatment. We want you to stay safe and healthy! ;)Links: Article about the IBD Innovate Conference- Crohn's & Colitis Foundation- USAEpisode of Oncology Overdrive from Healio with Dr. BarnellFDA Approves ColoSense test- Colorectal Cancer AllianceTune in to the Patient Advocacy Voices Podcast todayJoin Sanofi's Eric Racine to meet the unsung heroes leading patient advocacy organizationsListen on: Apple Podcasts SpotifyLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting, as well as Healio's top headlines from the meeting. Joseph A. Greer, PhD, discusses how early palliative care via telehealth had an equivalent impact on quality of life as in-person visits for patients with advanced non-small cell lung cancer. :27 Charu Aggarwal, MD, MPH, FASCO, further discusses these findings during a press briefing. 3:30 Heinz-Josef Lenz, MD, shares his thoughts on the first-line immunotherapy combination of nivolumab and ipilimumab in colorectal cancer. 4:35 Fumiko Chino, MD, discusses findings on the need for a more effective and transparent prior authorization process to ensure patients receive timely access to essential pain management. 7:09 Suneel Kamath, MD, provides an overview of findings assessing how the microbiome profile of early-onset pancreatic adenocarcinoma is distinct from that of average-onset disease. 10:22 Julie R. Gralow, MD, FACP, FASCO, discusses the important implications of a prospective study on young breast cancer survivors who attempted pregnancy and became pregnant. 12:54 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20240602/we-have-the-technology-telehealth-increases-access-to-palliative-care-for-cancer https://www.healio.com/news/hematology-oncology/20240602/practicechanging-data-support-firstline-immunotherapy-combination-in-colorectal-cancer https://www.healio.com/news/hematology-oncology/20240531/findings-highlight-need-to-improve-prior-authorization-process-for-cancer-pain-management https://www.healio.com/news/hematology-oncology/20240603/tumor-microbiome-profiles-in-pancreatic-cancer-differ-by-age-of-onset https://www.healio.com/news/hematology-oncology/20220611/intramuscular-recombinant-erwinia-asparaginase-active-safe-in-leukemia-lymphoma-subsets Glucose-lowering drugs reduce risk for obesity-related cancers Source: Lin CH, et al. Abstract 10508. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago. Chemotherapy regimen improves survival in advanced esophageal cancer Source: Hoeppner J, et al. Abstract LBA1. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago. Disclosures: Chino reports no relevant financial disclosures. Greer reports a consulting role with BeiGene; research funding from Blue Note Therapeutics and NCCN/AstraZeneca; and royalties from Oxford University Press and Springer Publishing Company. Please see the abstract for all other researchers' relevant financial disclosures.[JJ1] Kamath reports no relevant financial disclosures. Lenz reports honoraria from, consulting/advisory roles with, or travel, accommodations or expenses from 3T Biosciences, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Fulgent Genetics, G1 Therapeutics, GSK, Isofol Medical, Jazz Pharmaceuticals, Merck Serono, Oncocyte and Roche. Please see the abstract for all other researchers' relevant financial disclosures.
See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog There is a lot of New Medical Information that is important for patients to make healthy decisions about their care or the care of their loved ones that you won't hear about on the news. For new research to reach you, the public, a researcher or a drug company has to spend a great deal of money for the public relations people to push information into the light. I compiled the research I thought you might want to know about that has been discovered during the past 6 months. I always use these studies to educate my patients and to change my protocols for treatment, although many of them have been part of my practice for quite a while, because they just confirm what I have been seeing in my Integrative and preventive medical practice for years. The First Group of Discoveries Relate to Menopause, and the Risks of Being Menopausal The most recent article in Lancet confirmed what has been obvious to me in my GYN practice for years. I am not sure why this actually required a study to prove that Menopause is tied to a higher rate of depression and anxiety, in conjunction with insomnia, higher stress perception, and hot flashes. This study documented what the loss of estradiol, progesterone and testosterone can do to women in menopause. The sad fact is that this article doesn't tell the reader what they need to know, how to treat these symptoms. However, I will let you in on a self-discovered fact: The replacement of the hormones that disappear before and during menopause can be replaced in a non-oral delivery system to treat these symptoms. I have 40 years of medical practice that proves my findings that agree with the problem, and my treatment with hormones. The Lancet: Menopause tied to mental health issues in certain women A study found that when certain women are menopausal, they increase their risk of Depression, anxiety, bipolar disorder who experienced stressful life events, had poor sleep related to hot flashes, or had previous depressive symptoms of depression were more likely to develop menopause-related mental health problems. Researchers wrote in the journal The Lancet that some women escape the mental health effects of menopause altogether. HealthDay News (3/6) Another recent study about menopause discovers that a lack of estradiol in the post menopause causes women to have trouble thinking. I agree with that revelation, but why doesn't the research take the next step and suggest a treatment to prevent this result of hormone loss? Why doesn't the research tell us how to help women think by replacing their estradiol? Many other studies confirm that replacing estradiol will delay the onset of dementia by 10 years. Another study reveals that the replacement of testosterone will delay dementia it 10 more years. These studies occurred over 20 years ago, but this study doesn't cite them. Poor and worsening cognitive function is one of the most frequent complaints of my new patients coming to BioBalance Health® for treatment of menopause and low testosterone with bioidentical hormone pellets. Dr Maupin: I am continually reminded of the importance of testosterone and estradiol replacement is to aging men and women when they come back for their second pellet insertion and review their list of the symptoms they complained of before they started E and T pellets The most frequent response I witness when I ask if a woman's ability to think, do her job and stay organized is completely better after 3 months of Estradiol and Testosterone pellets, is crying with relief! Many patients are deeply worried that they are developing dementia, specifically Alzheimer's Disease when they first come to me, but are able to go back to work and or experience a renewed quality of life because their ability to think, they can now feel confident in their professions and careers. Dr M Estradiol associations with brain functional connectivity in postmenopausal women Testo, Abigail A. BS1; Makarewicz, Jenna BS1; McGee, Elizabeth MD2; Dumas, Julie A. PhD1 Author Information From the 1Department of Psychiatry 2Department of Obstetrics, Gynecology, and Reproductive Sciences, Larner College of Medicine, University of Vermont, Burlington, VT. The results illustrate the relationship between estradiol level and functional connectivity in postmenopausal women. They have implications for understanding how the functioning of the brain changes for individuals after menopause that may eventually lead to changes in cognition and behavior in older ages. © 2024 by The Menopause Society I have another problem with studies that should be shared with patients is that they often imply that menopausal women are “crazy” instead of saying that women after menopause develop mental health issues that can be treated with hormone replacement. Women who are menopausal are not mentally ill they are hormone deprived! I view this as a “slam” and divisive attack on aging women. The fact that if we gave women what they need …hormonal replacement ….they would not suffer the symptoms of mental health disorders. Menopause tied to mental health issues in some women A study found that women who experienced stressful life events, who had poor sleep due to nighttime hot flashes, or who had previous depressive symptoms or depression were more likely to have menopause-related mental health problems. Researchers wrote in the journal The Lancet that some women escape the mental health effects of menopause altogether. Full Story: HealthDay News (3/6) The Second Group of Articles Is About The Loss Of Estrogen In Menopause Causes Heart Failure and Atrial Fibrillation. This article from the European Society of Cardiology reveals that the longer women live without estrogen (e.g. is menopausal), the higher risk of developing heart failure and atrial fibrillation. Once again, there is no mention about how to prevent this disease! Why can't they study the women who replaced their hormones and compare them to the women who didn't? Hormone Therapy May Boost Weight Loss for Postmenopausal Women Who are Overweight or Obese On Semaglutide, Study Finds My practice BioBalance Health® has a weight loss program that is very effective for weight loss using Semaglutides, and terzipatide. For women who are menopausal we have found that they lose weight much more quickly if they are on E2 and T pellet hormone replacement. This research article confirms the findings of this study. If you are menopausal and have gained weight after menopause that is hormonal and the faster, you can get on non-oral estradiol and testosterone replacement then you will be more likely to get to your ideal weight! March 18, 2024 Hormone therapy may boost weight loss for postmenopausal women on Semaglutides. Healio (3/18, Welsh) reports, “Hormone therapy was associated with an improved weight-loss response for postmenopausal women with overweight or obesity treated with Semaglutides, according to cohort study results published in Menopause.” In the study, “postmenopausal women on hormone therapy had a higher percentage of total body weight loss at 3 (7% vs. 5%; P = .01), 6 (13% vs. 9%; P = .01), 9 (15% vs. 10%; P = .02) and 12 (16% vs. 12%; P = .04) months of semaglutide treatment compared with no hormone therapy.” How and Why to Treat Metabolic Syndrome Metabolic Syndrome is a combination of hypertension, high lipids, insulin resistance, obesity, prediabetes or diabetes, large abdominal measurement. This combination puts patients at risk for heart disease and early death. Many conditions and outcomes have been associated with metabolic syndrome, but now we have a treatment that can prevent one of the outcomes of this syndrome, the generic drug Metformin ER. Metformin, Cognitive Function, and Changes in the Gut Microbiome Endocrine Reviews, Volume 45, Issue 2, April 2024, Pages 210–226, Published: 21 August 2023 Article history Abstract The decline in cognitive function and the prevalence of neurodegenerative disorders are among the most serious threats to health in old age. Metformin can preserve cognitive function by treating metabolic syndrome and improving the gut biome that produces neurotransmitters. I am not naive enough to believe that the only thing that your brain needs to perform well is two sex hormones (E2 and T). This new research from the Endocrine Society describes how the generic, inexpensive medication Metformin ER, can help preserve an aging patient's ability to think. That is primarily because the brain has insulin receptors, and when a patient has insulin resistance brain cells don't receive enough blood-sugar to be able to think! By taking metformin ER (extended release) plus replacing estradiol plus testosterone in pellet form, the brain gets what it needs (blood sugar) and patients can think again! The second factor the researchers found to be important to brain health and problem solving, is healthy gut bacteria in the intestines. This requires eating whole foods, especially fruits and vegetables every day, and not eating fast food, alcohol, simple sugars, and preservatives that kill good bacteria. We recommend a daily probiotic by Mega + the lifestyle changes above. If you want to keep your ability to think for your whole life then you need E2 and T in pellet form if you are a woman and T if you are an aging male, plus Metformin ER daily and the above lifestyle changes. Metabolic Syndrome, Obesity, is the Biggest Risk for Cancer Metabolic syndrome may increase cancer risk by 30% People with metabolic syndrome had a 30% higher chance of developing cancer over the course of a decade after diagnosis, according to a study published in the journal Cancer. The researchers also studied inflammation by tracking C-reactive protein, concluding that elevated levels of the protein along with metabolic syndrome were “significantly associated with subsequent breast, endometrial, colorectal and liver cancers.” Full Story: National Public Radio (3/11) The struggle to stay young and healthy is a difficult fight but the most important battle that you will wage as an adult. If people knew the whole truth, would they stop overeating, drinking, smoking, avoiding exercise, or stop taking illicit drugs? I can only hope that if we convince people to take care of themselves better and replace the hormones that are missing as soon as they are clinically deficient, then they will also listen to the truth about the various ways to support their health and prevent disease. I also hope that the doctors who write articles and do research stop treating women like crazy people instead of the gender that actually runs the world and not only nurtures the children but also organizes homes and businesses. We are NOT crazy when we need hormones to be replaced (PMS, MENOPAUSE), we are experiencing symptoms of hormone-deprivation, and we just need to be treated with the hormones that are missing!
In this episode, host Shikha Jain, MD, speaks with Jan Kitajewski, PhD, about blending community need with scientific advancement, his role as the director of a cancer care center and more. • Welcome to another exciting episode of Oncology Overdrive :58 • About Kitajewski 1:08 • The interview 2:59 • Tell me about how you started and your pathway to this position. 3:26 • You have a very diverse background in various fields of medicine. Was there something that drew you to lead a cancer center? 6:15 • What are your thoughts on how institutions can shift their mindsets toward setting up research that is more inclusive of patient diversity in clinical trials? 9:44 • Jain and Kitajewski on The Immortal Life of Henrietta Lacks, mistrust in the health care system, and how institutions can empower their communities. 14:00 • What does a cancer center director do, and what are some things that people may be surprised to know about your position? 16:30 • Jain and Kitajewski on the University of Illinois Cancer Center applying for NCI designation, and what the process entails. 22:05 • Jain and Kitajewski on the challenges and successes that come with physician leadership when making changes at an institution. 29:28 • What is your vision for the future of the University of Illinois Cancer Center? 34:16 • If someone could only listen to the last minute of this episode, what would you want them to take away? 40:13 • How to contact Kitajewski 40:55 • Thanks for listening 41:35 Jan Kitajewski, PhD, is director of the University of Illinois Cancer Center and a professor and head of the department of physiology and biophysics. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Kitajewski can be reached via email kitaj@uic.edu. Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Kitajewski at the time of posting.
In the classic holiday film "It's a Wonderful Life", Clarence the angel says "remember, George, no man is a failure who has friends". In the holiday spirit, Your Doctor Friends took Clarence's words to heart, and present to you today the research behind how friendship keeps us healthy. In today's episode, we highlight the growing amount of evidence that supports friendships as a key aspect of our health, and, conversely, how social and emotional isolation often leads to poor health outcomes. The American Psychological Association summarizes, “given the clear benefits of friendship, psychologists say we should promote platonic social connection across society—including in school, at work, in public spaces (such as on public transportation), and through entertainment.” So let's do that today, shall we? And after listening to the episode, maybe reach out to a friend with a quick text, a silly photo, or an invite to meet up for a treat together. It might just help you live longer ;) And bonus dessert topic at the end, we talk about SOME GOOD NEWS in cancer treatment and survivorship! Happy holidays from Your Doctor Friends! We hope you're safe, happy, and healthy :) Resources for today's episode include: An American Psychological Association article titled "The science of why friendships keep us healthy". A Washington Post article titled "Friends can improve your health and well-being especially during the holidays". A systematic review/meta-analysis in PLoS One from 2023 titled "Social isolation as a risk factor for all-cause mortality" A Healio article titled "Cancer death rate drops by 33%, AACR report shows" The AACR press release for the Cancer Progress Report. The full AACR Cancer Progress Report 2023. For more episodes, limited edition merch, or to become a Friend of Your Doctor Friends (and more), follow this link! This includes the famous "Advice from the last generation of doctors that inhaled lead" shirt :) Also, CHECK OUT AMAZING HEALTH PODCASTS on The Health Podcast Network Find us at: Website: yourdoctorfriendspodcast.com Email: yourdoctorfriendspodcast@gmail.com Connect with us: @your_doctor_friends (IG) Send/DM us a voice memo/question and we might play it on the show! @yourdoctorfriendspodcast1013 (YouTube) @JeremyAllandMD (IG, FB, Twitter) @JuliaBrueneMD (IG) @HealthPodNet (IG)
In this episode of Meeting Mic, we bring you Healio's top headlines from ACR Convergence 2023. Eric Roberts, PhD, MPH, compares the uptake of biosimilar infliximab among patients with Medicare, Medicaid and private insurance in the U.S. :19 Shivani Garg, MD, MS, discusses how a therapeutic range of hydroxychloroquine blood levels may reduce the odds of high lupus disease activity. 2:09 Kaleb Michaud, PhD, discusses patients with rheumatoid arthritis who reported having long COVID in the past year demonstrating “many symptoms” of long COVID prior to initial infection. 12:00 Leonard H. Calabrese, DO, highlights the “year in review”, issues in vasculitis, and cautionary notes on CAR T cell therapies. 14:18 Jill Buyon, MD, discusses how pregnant patients with very low anti-Ro antibody titers of less than 1,000 units per mL have minimal-to-no risk for fetal atrioventricular block. 15:15 Read the full coverage here: https://www.healio.com/news/rheumatology/20231113/medicare-fails-to-keep-up-with-medicaid-private-market-on-infliximab-biosimilar-uptake https://www.healio.com/news/rheumatology/20231120/stay-within-hydroxychloroquine-therapeutic-threshold-to-reduce-active-lupus-flare-risk https://www.healio.com/news/rheumatology/20231116/patients-with-rheumatoid-arthritis-report-many-symptoms-of-long-covid-prior-to-infection @LCalabreseDO https://www.healio.com/news/rheumatology/20231113/pregnant-patients-with-low-antiro-titers-have-little-to-no-risk-for-fetal-heart-block Disclosures: Roberts, Garg, Michaud and Calabrese report no relevant financial disclosures. Buyon reports financial disclosures with Bristol-Myers Squibb, GlaxoSmithKline and Related Sciences.
In this episode of Meeting Mic, we bring you Healio's top headlines from ACG 2023. Paul Feuerstadt, MD, FACG, AGAF, discusses data that link health-related quality of life and microbiome composition among patients with recurrent Clostridioides difficile infection. :38 Edward V. Loftus Jr., MD, FACG, discusses results from the INSPIRE trial for ulcerative colitis. 7:52 Jan Wehkamp, MD, PhD, discusses results from the QUASAR study, in which Tremfya outperformed placebo in clinical response patients with ulcerative colitis. 12:08 Paul Feuerstadt also discusses the evolution of treatment for Clostridioides difficile infection, from antimicrobials to recently FDA-approved live biotherapeutics. 15:32 Thomas F. Imperiale, MD, discusses the results of the BLUE-C study, which evaluated the clinical performance of Cologuard, a next-generation, multitarget stool DNA test. 21:08 Read the full coverage here: https://www.healio.com/news/gastroenterology/20231023/video-rebyota-not-only-shuts-down-recurrence-also-affects-quality-of-life-in-c-diff https://www.healio.com/news/gastroenterology/20231025/video-risankizumab-a-great-option-for-patients-induces-clinical-remission-in-uc https://www.healio.com/news/gastroenterology/20231024/video-more-than-75-of-uc-patients-achieve-clinical-response-at-24-weeks-with-tremfya https://www.healio.com/news/gastroenterology/20231025/video-future-is-now-here-for-recurrent-c-difficile-thanks-to-live-biotherapeutics https://www.healio.com/news/gastroenterology/20231025/sensitivity-of-nextgeneration-cologuard-in-precancer-detection-numerically-exceeded-fit Disclosures: Feuerstadt reports financial relationships with Ferring Pharmaceuticals, Regeneron Pharmaceuticals, Seres Therapeutics and Takeda Pharmaceuticals. Imperiale reports grant and research support from Exact Sciences. Loftus reports financial relationships with AbbVie, Alvotech, Amgen, Arena, Avalo Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Exact Sciences, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Scopes, Janssen, KSL Diagnostics, Lilly, Morphic, Ono Pharma, Pfizer, Protagonist, Receptos, Robarts Clinical Trials, Scipher Medicine, Sun Pharma, Surrozen, Takeda, Theravance and UCB. Wehkamp reports no relevant financial disclosures.
In this episode, we dig through the data of lupus in Africa and speak with experts on the Lupus Gradient, the impact of malaria and what we can learn from it all. · Intro 0:12 · In the previous episode 0:30 · Lupus Gradient 2:01 · Back to Dr. Brian Greenwood 3:48 · Polyarthritis 4:04 · Rates of autoimmune diseases 6:00 · Malaria and mouse models 7:33 · Back to lupus 8:48 · First case of lupus 15:14 · Prevalence of lupus 17:15 · Papers on lupus 21:23 · Dr. Mickael Essouma 23:38 · Dr. Essouma, how did you conduct this study? 24:01 · Did you ever believe there was a gradient? 26:09 · Dr. Sandro Vento 30:56 · Dr. Vento, do you believe there was a lupus gradient? 31:51 · What are the connections to infectious disease? 38:51 · That's a wrap! 43:04 · Coming up in part 4 44:55 · Thanks for listening 45:05 Disclosures: Brown reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Essouma and Vento at the time of posting. Mickael Essouma, MD, is physician from Cameroon specialized in internal medicine at the University of Yaounde I in Cameroon, with a complimentary certificate on rheumatology from the EULAR online course and a certificate on lupus from the European Lupus Society (SLEuro). He is an advocate of lupus and other autoimmune diseases in Africans. Sandro Vento, MD, is the dean of faculty of medicine at the University of Puthisastra, Phnom Penh, Cambodia and a consultant and collaborating specialist at Mayo Clinic Center for Tuberculosis, WHO Collaborating Center. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Bae SC, et al. Arthritis Rheum. 1998;doi:10.1002/1529-0131(199812)41:123.0.CO;2-D. Bryc K, et al. Am J Hum Genet. 2015;doi:10.1016/j.ajhg.2014.11.010. Essouma M, et al. J Autoimmun. 2020;doi:10.1016/j.jaut.2019.102348. Gilkeson GS, et al. Lupus. 2011;doi:10.1177/0961203311404915. Micheletti SJ, et al. Am J Hum Genet. 2020;doi:10.1016/j.ajhg.2020.06.012. Symmons DP. Lupus. 1995;doi:10.1177/096120339500400303. Vento S, et al. Front Med. 2020;doi:10.3389/fmed.2020.00202.
Let's STRETCH this brain meal out, shall we? This week we are separating the entrees into courses with a little trip to the dessert cart! Jeremy serves up the FIRST COURSE today! Keep an eye out for Julie's course this THURSDAY! Let's gobble up the "brain nutrition" that helps YOU feel more empowered to appraise health stories in the news. Today's HEALTH HEADLINES include: Which is safer for athletes, artificial turf, or REAL GRASS playing surfaces? With the recent Achilles injury suffered by Aaron Rodgers on the turf field at the Jets home stadium, the debate between turf vs. grass was reignited, to say the least. What are the pros and cons of turf versus grass fields. What does the data suggest regarding injuries in athletes. Is there any increased risk of cancer to athletes playing on turf fields? Let YOUR DOCTOR FRIENDS give you the digestible chunks of info! PLUS our "Dessert Cart" contains quick bites about a new intra-uterine device (Jada) that can stop postpartum hemorrhage and save lives, as well as "sound colors" and picking what kind of "white noise" can help you! Resources for today's topics include: An ESPN article discussing the turf debate. The NFL Players Association's take on turf. American Journal of Sports Medicine article on injury rates on turf fields. AJSM systematic review on lower extremity injury rates on turf vs grass fields. AJSM article on padded vs non-padded turf fields. British Medical Journal article on concussions and artificial turf. OJSM article on ACL injuries on turf. Safe Healthy Playing Fields Inc website on costs of grass vs turf. Washington State Department of Health investigation of cancer and turf/crumb rubber. Healio article on the RUBY study about the Jada system for treating acute postpartum hemorrhage. Jen Hamilton (labor and delivery RN) viral TikTok about the Jada system. Washington Post article about "sound colors." For more episodes, limited edition merch, or to become a Friend of Your Doctor Friends (and more), follow this link! Also, CHECK OUT AMAZING HEALTH PODCASTS on The Health Podcast Network Find us at: Website: yourdoctorfriendspodcast.com Email: yourdoctorfriendspodcast@gmail.com Call the DOCLINE on 312-380-5005 and leave us a message. We will listen and maybe even respond/play it on the show! (Disclaimer: we will not answer specific medical questions or offer medical advice. Consult your healthcare professional with any and all personal health questions.) Connect with us: @your_doctor_friends (IG) @yourdoctorfriendspodcast1013 (YouTube) @JeremyAllandMD (IG, FB, Twitter) @JuliaBrueneMD (IG) @HealthPodNet (IG)
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Peter Slack, Greg Kunst, Rich Small and Uday Devgan, MD, FACS, FRCS, live from OSN New York. Welcome to the Eyeluminaries podcast :01 Review of episode 18 :18 Intro of Peter Slack 1:47 How did OSN start? 2:35 When did you get into meetings and where do you see meetings going? 5:40 Where do you see media going? 7:46 How did you end up running the Hawaiian Eye Meeting? 10:53 Intro of Greg Kunst 13:59s What will be the biggest challenges introducing a new paradigm for a traditionally surgical disease? 14:52 What can you tell us about Aurion's plans for cell therapy in other front and back of the eye disease, in addition to endothelial cell disease? 17:04 What should I be telling my patients who have future need for endothelial keratoplasty? 19:17 What is the status of Aurion in Japan? Is the competition on the horizon? 22:13 Intro of Rich Small 25:53 Why are you excited about the Encapsulated Cell Therapy Platform? 27:12 Why MacTel? 31:52 What is the status of the Neurotech BLA? 32:26 · Give us a good Jim Mazzo story 34:38 Intro of Uday Devgan, MD, FACS, FRCS(Glasg) 37:05 Tell us about how you got started producing one video per day 38:10 Tell us a story about a doctor from far away who is influenced by your teaching 40:38 If you could change one thing in residency training today, what would it be? 41:59 Preview of episode 20 43:51 Feedback, questions and guest suggestions at eyeluminaries@healio.com 44:04 Uday Devgan, MD, FACS, FRCS(Glasg), is Healio|OSN section editor for Ocular Surgery News. He is in private practice, specializing in cataract and refractive surgery, at Devgan Eye Surgery in Los Angeles and a full partner at Specialty Surgical Center in Beverly Hills, California. He has previously served as full clinical Professor of Ophthalmology at the Jules Stein Eye Institute at the UCLA School of Medicine as well as Chief of Ophthalmology at Olive View-UCLA Medical Center and has been actively involved in resident surgical teaching for over two decades. He owns and operates CataractCoach.com. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Greg Kunst is president, chief executive officer and board member at Aurion Biotech. He is focused in areas such as R&D, clinical development, corporate development, strategy, marketing, commercial, business development, market access and medical affairs with extensive knowledge of global health care markets (North America, Latin America, Europe, Asia), global commercialization and market development, upstream and downstream marketing, market access, and medical affairs for medical device, drug delivery systems, diagnostic systems, biotechnology, cell therapies, gene therapies, biologics, and pharmaceutical products. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Peter N. Slack is president and chief executive officer of The Wyanoke Group. Peter is past-Chairman and a current member of the Board of Trustees for the Center for Family Services, a nonprofit human services agency. Other professional titles and memberships have included Board of Directors of the International Association of Association Management Companies and Board of Directors of the American Medical Publishers Association. In addition, Peter is President of the Broadway Theatre of Pitman in Pitman, NJ. Disclosure: The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast. Rich Small is chief executive officer and member of the board of directors for Neurotech. He originally joined Neurotech in July 2007 as the company's chief financial officer. He has in excess of 30 years of both private and public life sciences experience and more than 40 years of overall financial and operational management. Previously Rich served as Senior Vice President and Chief Financial Officer of Point Therapeutics, a publicly traded biotechnology company focused in developing treatments for various cancers. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Devgan owns and operates CataractCoach.com. Hovanesian consults widely in the ophthalmic field. Kunst is president, chief executive officer and board member at Aurion Biotech. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Slack is president and chief executive officer of The Wyanoke Group. Small is chief executive officer and member of the board of directors for Neurotech. The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast.
This week you get TWO entrees with a little trip to the dessert cart! Julie and Jeremy picked some juicy stories from health headlines, strained out the inedible parts, and left you the sweet nectar. Let's gobble up the "brain nutrition" that helps YOU feel more empowered to appraise health stories in the news. This week's HEALTH HEADLINES include:Why do women pay more out-of-pocket for healthcare in the US? Julie breaks down a Deloitte analysis, and teaches Jeremy about the PINK TAX, and how it's EVERYWHERE (including in our insurance healthcare costs).Do LED light masks actually work? Do they result in younger-looking skin, less wrinkles, and fewer acne breakouts? Or are they just a scary cross-between-Jason-and-Ironman looking facial accessory??Our "Dessert Cart" contains quick bites about blood tests for long COVID, expiration dates for COVID tests, and cannabis-related car crashes and ER visits. Resources for today's topics include:Deloitte's analysis- "Hiding in plain sight: The health care gender toll." The CDC's Summary Health Statistics: National Health Interview Survey 2018.A 2019 Harvard Health Article- "Mars vs Venus: The gender gap in health."The Hysteria Podcast on Crooked Media (Sept 28 Episode features the Deloitte Analysis)(lol not scientific, but funny) A HuffPo Listicle about THE PINK TAX.American Society of Plastic Surgeons website on "What is LED light therapy and what are the benefits?"Harvard Health Article- "LED lights: Are they a cure for your skin woes?"Annals of Family Medicine article- "Blue-Light Therapy for Acne Vulgaris: A Systematic Review and Meta-Analysis".Cochrane Database of Systematic Reviews- "Light therapies for acne."An article from Photomedicine and Laser Surgery on red-light therapy for facial skin. A Healthline article- "LED Light Therapy for Skin: What to Know."Healio article- "Traffic injury ED visits involving cannabis grow over recent years."For more episodes, limited edition merch, or to become a Friend of Your Doctor Friends (and more), follow
Welcome back to You Had Me At Eat season 2. Jules and Erica had a quick break while Jules moved her youngest with a specialty diet into the college dorms! Jules and Erica also took a trip to Tucson, Arizona where they explored Erica's favorite gluten-free bakery, and visited the Desert Sonoran Museum in 107 degrees. You Had Me At Eat is also nominated for Best Gluten-Free Podcast in the Gluten-Free Buyers' Guide Gluten-Free Awards for 2024, and Erica was nominated for the Patient Voice award for the Healio Gastroenterology Disruptive Innovators award! Listen in and welcome back!RESOURCES:Spokin Food-Allergy-Friendly CollegesGluten-Free in College by gfJulesDedicated gluten-free bakery in Tucson, AZGluten-Free Buyers Guide gluten-free awards 2024 - be sure to vote for Erica for best gluten-free personality, gfJules for everything else, and You Had Me At Eat podcast!Healio Gastroenterology Disruptive Innovator award - Erica was nominated!Contact/Follow Jules & Erica Tweet us @THEgfJules & @CeliacBeast Find us on IG @CeliacandTheBeast & @gfJules Follow us on FB @gfJules & @CeliacandTheBeast Email us at support@gfJules.com Find more articles, recipes & info at gfJules.com & celiacandthebeast.com Thanks for listening! Be sure to subscribe!**some links may be affiliate links; purchasing through these links will not cost you more, but will help to fund the podcast you ❤️
In this episode, hosts Shikha Jain, MD, Douglas H. Jones, MD, Amy Comander, MD, Dagny Zhu, MD, Don Dizon, MD, and Mark A. Lewis, MD, discuss the new social media platform, Threads and how physicians can use it for their practice. • Welcome to another exciting episode of Oncology Overdrive :57 • The topic 1:10 • How many have created a profile on Threads? Why or why not? 2:59 • Dr. Jain has a Thread profile but is unsure how to get more engagement 3:20 • Dr. Lewis has convinced coworkers to use social media but has not used Threads yet 4:54 • Dr. Dizon has a Thread profile but notes that leaving other platforms is leaving those communities and starting all over on a new platform 6:25 • Giving Threads more time to pick up followers and engagement 11:18 • Dr. Zhu has a Thread profile and found it easy to create but engagement is not the same as other platforms 12:17 • Tips and tricks to sharing content on socials, especially Threads 14:33 • Trouble with other social media platforms 17:55 • Tips and tricks to building a community on a social media 20:20 • The power of social media platforms and engagement in established communities 22:30 • Fighting misinformation 25:13 • Platforms versus audience 27:15 • How would you like to see Threads change as a platform? 31:21 • What is the power of TikTok in terms of getting movement among communities? 33:31 • How do you create a profile on Threads? 40:30 • Level of engagement: Twitter vs. Threads 43:31 • The overwhelming number of platforms 52:29 • What is the best platform for physicians to use? 53:41 • Sharable content to post across other platforms 55:34 • Final thoughts 58:09 • Thanks for listening 1:02:13 Douglas H. Jones, MD, is the cofounder of Global Food Therapy, cofounder and president of Food Allergy Support Team and director of Rocky Mountain Allergy at Tanner Clinic. You can follow him on Threads @drdouglasjones. Amy Comander, MD, DipABLM, is director of breast oncology and survivorship at the Massachusetts General Hospital Cancer Center in Waltham and at Newton-Wellesley, and medical director of the Massachusetts General Hospital Cancer Center in Waltham. She is director of the Lifestyle Medicine Program at the Massachusetts General Hospital Cancer Center. She is also an instructor in medicine at Harvard Medical School. You can follow her on Threads @dramycomander. Shika Jain, MD, FACP, is an associate professor of medicine with tenure in the division of hematology, oncology and cell therapy at the University of Illinois Cancer Center in Chicago. She is the director of communication strategies in medicine and associate director of oncology communication and digital innovation. She also is consulting editor for Healio Women in Oncology, as well as host of Healio's Oncology Overdrive podcast. You can follow her on Threads @shikajainmd. Dagny Zhu, MD, is a cornea, cataract, and refractive surgeon and medical director and partner at NVISION Eye Centers in Rowland Heights, CA. You can follow her on Threads @dzeyemd. Don S. Dizon, MD, FACP, FASCO, is head of community outreach and engagement at the Cancer Center at Brown University and head of the breast and pelvic malignancies program at Lifespan Cancer Institute. You can follow him on Twitter (X) and TikTok @drdonsdizon. Mark A. Lewis, MD, is the director of gastrointestinal oncology at Intermountain Healthcare in Murray, Utah, and a medical oncologist specializing in cancers of the gastrointestinal tract and accessory organs. You can follow him on Twitter (X) @marklewismd. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Disclosures: The moderators and panelists report no relevant financial disclosures.
In this episode of The Just M.S. Show, we delve into the remarkable advances in the world of Multiple Sclerosis (MS) treatment and detection. From AI models predicting MS risk before symptoms appear to the groundbreaking addition of MS medications to WHO's Essential Medicines List, the hope for effective treatment is brighter than ever. We discuss the efficacy of ocrelizumab as a first-line treatment and the shift in disease-modifying therapy prescription towards oral medications. We also share personal stories of aging with MS, and the interplay between MS progression and normal aging processes. Finally, we explore fascinating research insights on how gut microbiome could trigger MS onset, and how Biogen's acquisition of Reata Pharmaceuticals might shape the future of rare disease treatments. Join us for these discussions and more as we navigate through the dynamic landscape of MS research, treatment, and personal experiences.Intro – Justin kicks off the episode by introducing the listeners to the engaging content of the day which includes the latest breakthroughs in Multiple Sclerosis (MS) treatment, research, and personal experiences.AI in Healthcare – Justin dives deep into a PRNewswire article highlighting the role of artificial intelligence (AI) and machine learning in predicting MS and minimizing laboratory errors.https://www.prnewswire.com/news-releases/artificial-intelligence-models-predict-multiple-sclerosis-detect-contaminated-lab-samples-301883543.htmlEssential Medicines Update – Discussion on the World Health Organization's new additions to the Model Lists of Essential Medicines for MS treatment, providing an analysis of how this could influence the lives of patients across the globe.https://www.who.int/news/item/26-07-2023-who-endorses-landmark-public-health-decisions-on-essential-medicines-for-multiple-sclerosisOcrelizumab Efficacy – Detailed analysis of a Healio article revealing the effectiveness of ocrelizumab as a first-line treatment for MS, backed by a comprehensive 9-year research study.https://www.healio.com/news/neurology/20230726/video-ocrelizumab-effective-as-firstline-treatment-for-msAging with MS – In this heartfelt segment, Justin presents the narrative of Trevis Gleason from Everyday Health, where he shares his personal journey with aging and MS, which many listeners will relate to.https://www.everydayhealth.com/columns/trevis-gleason-life-with-multiple-sclerosis/aging-with-ms/Prescription Shifts – Delving into a study from HealthDay News, Justin discusses the noticeable shift towards oral disease-modifying therapies in MS treatment.Gut Microbiome and MS – An exciting segment discussing research from Ludwig-Maximilians-Universität München about the relationship between the gut microbiome and the activation of auto-aggressive T cells in MS.Biogen and Reata Acquisition – In the final part of the episode, Justin tackles Biogen's recent acquisition of Reata Pharmaceuticals, offering insights into how this might shape the future of the rare disease drugs market, including MS treatment.https://www.washingtonpost.com/business/2023/07/28/biogen-deal-for-reata-signals-a-turn-to-rare-diseases/9cbf4a84-2d67-11ee-a948-a5b8a9b62d84_story.htmlOutro – Wrapping up, Justin encourages the listeners to stay positive, informed, and connected, and invites them to join the next episode of "The Just M.S. Show".Listeners are encouraged to refer to the episode description for linkThe Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.www.justmultiplesclerosis.com
Laura B. Enyedi, MD, and Dagny Zhu, MD, discuss contract negotiations and the gender wage-gap in ophthalmology with Lisa Nijm, MD, JD. · Welcome to another episode of Mend the Gap :01 · The topic :45 · Introduction Lisa Nijm, MD, JD 1:10 · What are the most important parts of contract negotiation? 4:20 · What are the items that are the most important to negotiate? 6:09 · Do you find a middle ground when it comes to negotiations? 11:04 · Receiving backlash for being “too aggressive” in negotiations 15:05 · Approaching negotiations with confidence 19:17 · Gender pay-gaps 20:14 · Women physicians and inequality 27:52 · For more information, go to realworldophthalmology.com and wioonline.org 31:50 · Thank you 33:20 We'd love to hear from you! Send your comments/questions to podcast@healio.com. Follow us on Twitter @Healio_OSN. Laura B. Enyedi, MD, is professor of ophthalmology and pediatrics at Duke Eye Center and medical director of South Durham Ophthalmology in North Carolina. Lisa Nijm, MD, JD, is a cornea, cataract and LASIK surgeon at Warrenville Eyecare & LASIK, licensed attorney, innovator and assistant professor at the University of Illinois Eye & Ear Infirmary. Dagny Zhu, MD, is a cornea, cataract, and refractive surgeon and medical director and partner at NVISION Eye Centers in Rowland Heights, CA. She can be reached on twitter @DZEyeMD. Disclosures: Enyedi and Zhu report no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Nijm at the time of posting.
In this episode of Meeting Mic, we bring you Healio's top headlines from DDW 2023. Jessica R. Allegretti, MD, MPH, reviews the results of a Tremfya study presented at the meeting. :09 Ken Blount, PhD, discusses restoration of gut microbiota and clonal engraftment after treatment with Rebyota. 4:07 Evan S. Dellon, MD, MPH, explains the improvements of mepolizumab seen in patients with eosinophilic esophagitis. 10:50 Jessica R. Allegretti also discusses the treatment with Rebyota in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection. 15:16 Shrujal Baxi, MD, MPH, describes the use of artificial intelligence for polyp detection for colorectal cancer. 19:26 Paul Limburg, MD, MPH, AGAF, reviews the revised guidelines and the push for non-invasive screening methods for colorectal cancer. 24:07 Read the full coverage here: https://www.healio.com/news/gastroenterology/20230509/video-patients-with-uc-achieve-symptomatic-remission-as-early-as-week-4-with-tremfya https://www.healio.com/news/gastroenterology/20230509/video-distinctive-shift-in-gut-microbiota-after-rebyota-treatment-for-c-difficile https://www.healio.com/news/gastroenterology/20230510/video-mepolizumab-for-eoe-does-not-yield-prominent-symptom-improvement-after-6-months https://www.healio.com/news/gastroenterology/20230509/video-no-change-in-concomitant-medications-after-rebyota-for-recurrent-c-difficile-ibd
This week on Pharm5 Humira biosimilars Vyvanse, Symbicort, and more losing patents this year Rezafungin approval Senate Committee meets on drug shortages COVID-19 declassified Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD References: Sandoz receives US FDA approval for biosimilar Hyrimoz® (Adalimumab-adaz) high-concentration formulation. Novartis. http://bit.ly/3lBJ1rK. Published March 21, 2023. Accessed March 23, 2023. Humira [package insert].North Chicago, IL: AbbVie Inc. Accessed March 23, 2023. Stonehill M. Humira exclusivity expires in 2023: Will biosimilar boom benefit patients or industry? Healio. http://bit.ly/3lzQrvs. Published January 17, 2023. Accessed March 23, 2023. Amjevita™ (Adalimumab-Atto), first biosimilar to Humira®, now available in the United States. Amgen. http://bit.ly/3Z9gesm. Accessed March 23, 2023. Kansteiner F, Sagonowsky E, Becker Z, Dunleavy K, Liu A. The top 10 drugs losing us exclusivity in 2023. Fierce Pharma. https://bit.ly/3LGsm0N. Published March 13, 2023. Accessed March 23, 2023. FDA drug shortages. FDA Drug Shortages. http://bit.ly/3LLEAoY. Accessed March 23, 2023. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. www.ginasthma.org. Accessed March 23, 2023. Cidara Therapeutics, Inc. Cidara Therapeutics and Melinta Therapeutics announce FDA approval of Rezzayo™ (rezafungin for injection) for the treatment of Candidemia and invasive candidiasis. GlobeNewswire News Room. http://bit.ly/40utHMl. Published March 22, 2023. Accessed March 23, 2023. Thompson GR, Soriano A, Cornely OA, et al. Rezafungin versus Caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): A multicentre, double-blind, double-dummy, randomised phase 3 trial. The Lancet. 2023;401(10370):49-59. doi:10.1016/s0140-6736(22)02324-8 FDA Approves Rezzayo, a Novel Echinocandin. Infectious Disease Special Edition. https://bit.ly/3TAbn2d. Published March 23, 2023. Accessed March 23, 2023. Gauthier T. Rezafungin (Rezzayo). IDStewardship. http://bit.ly/3LHBn9X. Accessed March 23, 2023. O'Mary L. Cases of potentially deadly fungus jump 200%: CDC. Medscape. http://bit.ly/40lSRwC. Published March 22, 2023. Accessed March 23, 2023. Drug shortage health and national security risks: Underlying causes and needed reforms. Committee on Homeland Security & Governmental Affairs. https://bit.ly/3ZdX846. Published March 22, 2023. Accessed March 23, 2023. Biden signs Bill on COVID origins declassification. AP NEWS. http://bit.ly/3JCsOKJ. Published March 20, 2023. Accessed March 23, 2023. Pradhan R. End of Covid emergency will usher in changes across the US Health System. Kaiser Health News. http://bit.ly/40xC0H0. Published March 22, 2023. Accessed March 23, 2023.
In this conversation, Daniel Belkin and Mitch Belkin interview Adam J Brown, MD about the field of Rheumatology, autoimmune diseases, and his podcast Rheuminations. They discuss the history of gout, plaquenil, the relationship between infectious diseases and rheumatologic conditions, the inflammasome, autoinflammatory disorders, vasculitis, fibromyalgia, Covid, and much more.Who is Adam J Brown?Dr. Adam J. Brown is a Rheumatologist at the Cleveland Clinic. Dr. Brown is the author of the book Rheumatology Made Ridiculously Simple. He is also the host of the Healio podcast Rheuminations, which focuses on autoimmunity, rare diseases, and the history of medicine. References:Twitter - @AdamJBrownMDAdam J Brown's Quiz Platform Rheum and BoardsHealio Rheuminations Podcast Support the showFollow us at @ExMedPod Subscribe to our Youtube channelConsider supporting us on Patreon
Susan Weiner SPEAKER | AUTHOR MS | RDN | CDCES | FADCES Susan Weiner is an award-winning nutrition, health and diabetes expert and the owner of Susan Weiner Nutrition, PLLC. Susan served as the 2015 ADCES Diabetes Educator of the Year and is an ADCES fellow. Among her many distinguished awards, she is the recipient of the 2019 Metropolitan New York Association of Diabetes Educators Advocate of the Year Award and the 2018 Media Excellence Award from the New York State Academy of Nutrition and Dietetics. Susan is the “Diabetes in Real Life” columnist for Endocrine Today and is the on-air host for video interviews and content for Healio.com. She is the co-author of The Complete Diabetes Organizer: Your Guide to a Less Stressful and More Manageable Diabetes Life and Diabetes: 365 Tips for Living Well. Susan has extensive TV, radio, podcast and video experience and is well versed in media communications. Susan is a well-respected national and international speaker on a variety of topics related to nutrition, diabetes, wellness and health, and has authored dozens of articles in peer reviewed journals. She has authored and been cited in over 300 articles for popular press, consumer publications and online sites. Susan earned her Master's Degree in Applied Physiology and Nutrition from Columbia University. Susan Weiner, MS RDN CDCES FADCES Owner and Clinical Director, Susan Weiner Nutrition PLLC 2015 ADCES Diabetes Educator of the Year Diabetes In Real Life columnist, Endocrine Today New Website! www.susanweinernutrition.com - @susangweiner The Happy Diabetic Kitchen Podcast is sponsored by US MED Please visit https://www.usmed.com/happydiabetic/ today for a free benefits check US MED WELCOMES THE HAPPY DIABETIC COMMUNITY When it comes to your health, nothing else matters. That's why with US MED, your health matters to us. From insulin pumps, continuous glucose monitors, blood glucose strips and more, your well-being is in the right hands with the experts at US MED. Call Us : 888-885-0012
In this episode, host Shikha Jain, MD, speaks with Michael Roizen, MD, author and chief wellness officer at the Cleveland Clinic, about developing tools that can help lead to a longer life, public health messaging in media and more. Welcome to another exciting episode of Oncology Overdrive :14 About Roizen :20 The interview 1:01 How did you get to where you are today, and what was your journey into medicine, health care and everything you are doing outside of clinical medicine? 1:30 How do we de-age ourselves, and what do we do to reboot ourselves? 4:30 Why have we not had a national movement toward this when this is something that many people care so much about? 9:39 Jain and Roizen on retirement age, life expectancy and medical benefits 11:38 Do you think there are any modifications or anything we should think about differently now that COVID is a part of our everyday life? 17:34 What are you covering in this book [The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow]? What is its purpose? 19:43 For those of us who are parents, does it matter if you start programming cells from a young age, or is this more for adults? 22:50 How did you get an Emmy? 27:12 What do you think of how communication to the public has changed? … What do you think about where we are going and how things have evolved over the years? 29:08 What's next for you? … How do you find the time to do all of this? 32:38 About Jain's non-profits and Roizen's involvement in gender equity movements in medicine 38:09 If someone could only listen to the last minute of this episode, what would you want them to take away? 44:14 How to contact Roizen and get his book 45:03 Thanks for listening 46:16 Michael F. Roizen, MD, is the emeritus chief wellness officer at the Cleveland Clinic, a professor at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, and author of four #1 New York Times best-selling books. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Roizen can be reached via email at info@greatagereboot.com, or on the website GreatAgeReboot.com. Find The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow wherever you get your books! Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm Roizen's financial disclosures at the time of publication.
In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio's top headlines from the meeting. Virginia G. Kaklamani, MD, DSc, professor of medicine in the division of hematology/oncology at UT Health San Antonio and leader of the breast cancer program at UT Health San Antonio MD Anderson Cancer Center, reviews an abstract presentation on the impact of cyclin-dependent kinase 4/6 inhibitor therapy in patients with advanced breast cancer :00 Aditya Bardia, MD, MPH, director of the breast cancer research program at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School, discusses a study on trastuzumab-deruxtecan and its response rate in patients with early breast cancer 5:00 Sara A. Hurvitz, MD, FACP, medical oncologist at UCLA Health, Santa Monica Medical Center, associate professor at David Geffen School of Medicine at UCLA, medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, and director of the breast cancer clinical trials program at UCLA, examines trastuzumab-deruxtecan's effect on patients with breast cancer who were previously treated with trastuzumab and a taxane. 10:00 Read the full coverage here: Longer CDK 4/6 inhibitor therapy enhances elacestrant benefit in metastatic breast cancer Elacestrant extends PFS among certain women with metastatic breast cancer Trastuzumab deruxtecan ‘new gold standard' in second line for breast cancer subset Ribociclib regimen may be superior to chemotherapy in advanced breast cancer Breast cancer specialist receives lecture award Genomic assay may predict ovarian function suppression benefit in breast cancer subset Disclosures: Bardia reports research funding from or consultant/advisory roles with AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Immunomedics/Gilead Sciences, Merck, Novartis, Pfizer, Radius Health and Sanofi. Hurvitz reports honoraria from Daichi Sankyo and research funding to her institution from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX Therapeutics, Daiichi Sankyo, Dantari, Dignitana, Eli Lilly, G1 Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, MacroGenics, Novartis, OBI Pharma, Orinoco Pharmaceuticals, Pfizer, Phoenix Molecular Designs, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Samumed, Sanofi, Seagen and Zymeworks. She also reports her spouse is a shareholder/stockholder in Ideal Implant. Kaklamani reports honoraria from, consultant/advisory roles with, speakers bureau roles with or other relationships with AstraZeneca, Daiichi Sankyo, Genentech, Genomic Health, Gilead Sciences, Novartis, Pfizer and Puma Biotechnology. Please see the abstract for all other researchers' relevant financial disclosures.
In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio's top headlines from the meeting. Alfred Kim, MD, discusses some key take-home points from the Long COVID presentation :18 Giovanni Adami, MD, reviews the impact of tofacitinib on fracture risk in patients with rheumatoid arthritis and the effect of glucocorticoids on bone density. 3:39 Leonard Calabrese, DO, gives a long-view of the meeting and the sessions he attended. 6:06 Paul Emery, MD, discusses results of a phase 2 study of peresolimab for adults with rheumatoid arthritis. 9:32 Read the full coverage here: https://www.healio.com/news/rheumatology/ 20221112/understanding- of-long-covid-shifting-at- breakneck-speed https://www.healio.com/news/rheumatology/ 20221122/bonesafe-glucocorticoid- dose-hard-to-find-in- rheumatic-musculoskeletal- diseases https://www.healio.com/news/rheumatology/ 20221121/pd1-agonist-generates-a-bit-of-excitement- in- rheumatoid- arthritis ACR: Varicella vaccine strongly recommended in all immunosuppressed adults ‘Anatomy inventory' fosters more inclusive care for transgender, non-binary patients 'Strange times': Prescribing methotrexate legally ‘low risk' Post-Roe Disclosures: Adami reports consultant roles with Amgen, BMS, Eli Lilly, Fresenius Kabi, Galapagos, Theramex and UCB. Calabrese reports consultant roles with AstraZeneca and GSK. Emery reports relationships with AbbVie/Abbott, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galapagos, Gilead, Novartis, Pfizer, Roche and Samsung. Kim reports no relevant financial disclosures.
It's in the News.. the top diabetes stories of the past seven days. This week, the first drug to prevent T1D for any length of time is approved, Eli Lilly takes a financial hit from a Twitter impersonation stunt, Medtronic's 7-day pump infusion set is ready for consumers, Dexcom's G7 gets great reviews from older folks and educators for ease of use, a new study about light at night and diabetes and more! Learn more about the T1D Exchange: www.t1dexchange.com/stacey Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX And by my new book “Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes” available on Amazon in paperback and for kindle. XX Our top story this week, the US U.S. Food and Drug Administration approves teplizumab, the first drug to delay the onset of type 1 diabets. We've been following this for a long time and I'll ink up our previous interviews with Provention Bio, the company that makes it. The brand name will be Tzield (teplizumab-mzwv) and it's an injection to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes. Tzield is administered by intravenous infusion once daily for 14 consecutive days. Lots of questions here and we'll follow up with an interview and more as soon as I can. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes https://diabetes-connections.com/delaying-a-t1d-diagnosis-the-fda-considers-teplizumab/ XX Our top story this week – the kerfuffle over on Twitter where a couple of accounts spoofed Ely Lilly. The insulin makers stock tanked 6% over just one day late last week, wiping billions of dollars from its market cap. On Nov.10, someone pretending to be Lilly's corporate account tweeted: “We are excited to announced insulin is free now.” You may know that Twitter under new owner Elon Musk was verifying any account with any name for just 8-dollars. Another verified but fake Lilly account tweeted profanities and taunted people who use insulin with higher pricing, again, also fake. Other major insulin makers Sanofi and Novo Nordisk were also caught up in the crossfire, with their stock prices dipping and questions over the high cost of insulin back in the headlines. In the understatement of the year, Lilly CEO David Ricks said – quote – “it probably highlights that we have more work to do to bring down the cost of insulin for more people” XX Mice with diabetes appeared cured after transplantation of insulin-secreting pancreatic islet cells, according to a Stanford Medicine study. The animals' immune systems were coaxed to accept the donated cells prior to transplantation through a three-pronged process that could be easily replicated in humans, the researchers said. No immune-suppressing treatments were necessary after the transplant to prevent rejection of the foreign islet cells. The technique, which builds on earlier work at Stanford Medicine, may open the door to a new type of organ transplant that doesn't require an immunologically matched donor or years on immune-suppressing medication. The difference here is that they do two transplants.. first doing a partial blood stem cell transplant which makes the new pancreas cells recognized as the body's own and less likely to be rejected. Long way to go here, but promising idea. https://med.stanford.edu/news/all-news/2022/11/islet-transplant-diabetes.html XX The first and only 7-day infusion set is ready to go.. after approval more than a year ago – in September of 2021, Medtronic says customers can now order the Medtronic Extended for the 600 and 700 series pumps. In clinical studies of the Medtronic Extended infusion set, study participants observed a decrease in the number of times an infusion set needed to be changed by 50% and the number of infusion set failures associated with high glucose levels was lowered.3,4 Study participants using the Medtronic Extended infusion set commented on the new infusion set being more comfortable to wear compared to their previous infusion sets and were happy with the longer wear feature in helping reduce the overall burden of insulin pump therapy.3,4 Additionally, use of the Medtronic Extended infusion set is estimated to result in annual costs savings of insulin of up to 25% due to a reduced number of infusion set and reservoir changes that result in unrecoverable insulin, as well as plastic waste reduction of up to 50%. https://www.prnewswire.com/news-releases/medtronic-launches-worlds-first-and-only-infusion-set-for-insulin-pumps-that-doubles-wear-time-up-to-7-days-in-us-301677790.html XX Recall for omnipod. This is an issue with the Omnipod 5 Controller charging port and cable. This does not impact the Omnipod 5 Pod, the Omnipod® DASH Insulin Management System, the Omnipod® Insulin Management System, or compatible Android smartphone devices that have the Omnipod 5 App installed. No serious injuries have been reported, but insulet has received reports tht the omnipod 5 controller chargting port or cable is discoloring or even melting due to excess heat. Customers are instructed to called insulet or login to an fda site. I'll link up all of that info in the show notes. at 1-800-6). Additional informati41-2049, which is available 24 hours a day, 7 days a week. Alternatively, Omnipod 5 users can utilize the FDA's MedWatch Adverse Event Reporting program either online (www.fda.gov/medwatch/report.htmExternal Link Disclaimer), by regular mail, or by fax (1-800-FDA-0178on, including instructions to customers to mitigate risk, can be found on the Company's website at www.omnipod.com/insulet-alertsExternal Link Disclaimer. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/insulet-issues-nationwide-voluntary-medical-device-correction-omnipodr-5-controller XX Small study shows that using the Dexcom G7 is easier for older adults to insert and use. Results indicate that G7 CGM system required half as many steps to set up and deploy as the G6 system, with the system's system usability scale survey scores indicating excellent usability. The current study was launched to better understand ease of use and task burden of uptake of Dexcom's G7 CGM system. To do so, investigators designed their study as a formal task analysis with the intent of identifying the number and complexity of tasks associated with deployment of the G7 CGM system compared to the fifth- and sixth-generation systems in adults aged 65 years or older. A cohort of 10 older adults with no prior CGM experience and 10 CDCESs were recruited for inclusion in the investigators' formal task analysis. This analysis assessed ease of use among CDCESs through a survey after hands-on insertion and initiation of the system. For older adults in the study, ease of use was assessed using system usability scale (SUS) survey scores. In the post-test survey and SUS survey given to older adults, no responses lower than neutral were recorded and the SUS score for setup and insertion of the G7 system was 92.8, which investigators noted was reflective of an excellent usability rating. https://www.endocrinologynetwork.com/view/study-finds-dexcom-g7-set-up-is-easier-requires-fewer-tasks-for-older-adults-than-previous-generations XX Control IQ for people with type 2 works well and is safe. New study from Tandem Diabetes Care shows people with type 2 spent 3.6 hours a day long in target range after switching to the tslim x2 pump / Dexcom system from multiple daily injections or basal insulin only https://www.medtechdive.com/news/tandem-pump-dexcom-CGM-Type-2-diabetes/636448/ XX New program from Walgreens to help give more people access to information and diabetes services. Walgreens is teaming up with its Health Corners and third-party clinics to offer free A1C and blood glucose testing and diabetes education during November, Diabetes Awareness Month. For participating locations, visit Walgreens.com/FreeDiabetesScreening and I'll link that up. Walgreen is the largest provider of continuous glucose monitors including the Dexcom G6 and FreeStyle Libre 2 which track glucose levels all day and night – fewer finger sticks required. 7. Affordable care options and tools including Walgreens Prescription Savings Club and Find Rx Coverage which offer insulin savings programs and affordable, predictable copayments on select insulins. Walgreens Find Care provides access to in-person and virtual healthcare expertise from the comfort of one's home. XX Sleeping in a room exposed to outdoor artificial light at night may increase the risk of developing diabetes, according to a huge study of nearly 100,000 Chinese adults. People who lived in areas of China with high light pollution at night were about 28% more likely to develop diabetes than people who lived in the least polluted areas. We told you about a study published earlier this year that showed Sleeping for only one night with a dim light, such as a TV set with the sound off, raised the blood sugar and heart rate of the young people during the sleep lab experiment. These researchers caution that any direct link between diabetes and nighttime light pollution is still unclear, however, because living in an urban area is itself a known contributor to the development of diabetes https://www.cnn.com/2022/11/14/health/night-light-pollution-diabetes-sleep-wellness/index.html XX Researchers are recruiting 20,000 children for a trial to try to identify those at high risk of developing type 1 diabetes. If left undiagnosed or untreated, the condition can lead to life-threatening complications. The trial, led by the University of Birmingham, could mean access to new treatments for children at high risk. The researchers say it may also offer insights that could make screening for type 1 diabetes a possibility. ADVERTISEMENT Type 1 diabetes is an autoimmune condition where the immune system attacks and destroys cells in the pancreas which produce insulin. Insulin is crucial because it moves energy from food from the blood to the cells of the body - without it, the body cannot function properly. Approximately 29,000 children in the UK currently have type 1 diabetes, out of a total of about 400,000 people. For them, managing the condition involves injecting insulin and testing blood glucose levels regularly. The condition is very different to type 2 diabetes, which is often linked to poor diet or an unhealthy lifestyle. The organisers want children aged three to 13 to sign up for the trial, which will analyse their blood - through finger prick and vein tests - for autoantibodies. These are linked to the development of type 1 diabetes. Those with two or more autoantibodies have an 85% chance of having the condition within 15 years, and are almost certain to develop it in their lifetime. 'A simple test could have saved my son' Parth Narendran, professor of diabetes medicine, and Dr Lauren Quinn, clinical research fellow at the University of Birmingham, said there was a need to explore if screening children for type 1 diabetes in the UK would be possible in the UK. "Screening children can reduce their risk of DKA (diabetic ketoacidosis) at diagnosis around fivefold and can help them and their families settle into the type 1 diagnosis better," they said. DKA is a life-threatening complication of type 1 which can occur when diagnosis does not happen quickly. Rachel Connor, director of research partnerships at JDRF UK, which is co-funding the study, said new drugs that target the immune system were progressing through trials. "We are demonstrating that it is possible to delay the need for intensive insulin treatment in those most at risk. When these drugs become available in the UK, we need to be ready to use them straight away," she said. Dr Elizabeth Robertson, from Diabetes UK, which also funded the study, said: "Extra years without the condition means a childhood no longer lived on a knife-edge of blood sugar checks and insulin injections, free from the relentlessness and emotional burden of type 1 diabetes." https://www.bbc.com/news/health-63622084 XX New study on pancreas transplants. These researchers say Up to 90% of people who received a pancreas transplant enjoy freedom from insulin therapy and the need for close glucose monitoring. Biggest drawback is having to take immunosuppressants for the rest of their life. The number of pancreas transplants has declined in recent years. New paper this week in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. Another downside is that this isn't a long-term cure.. the paper says the median graft survival is around eight years and the transplanted pancreas does not always work well, so the patient might not be completely insulin-free. However, I do believe that the combined kidney/pancreas transplant should be considered for all patients with type 1 diabetes with an indication for a kidney transplant.” https://www.healthline.com/health-news/type-1-diabetes-the-benefits-and-limitations-of-a-pancreas-transplant XX Medtrnoic sending emails out regarding the CareLink™ Software outages. . For most of our customers, we were able to resolve the issue relatively quickly through an application fix that took effect when individuals logged out and then logged back into their CareLink™ accounts (reminder of these recommended actions available here). But we know this was not the experience for all, and for some of you the experience was extremely frustrating and lasted longer. Medtnoic is still working to resolve the issue for some customers. They stress this was not because of a security breach but don't give further details. https://app.medtronicdib.mdtpatient.com/e/es?s=357929245&e=822474&elqTrackId=b0ce7494b5bd47ad9b9c672c71086a1c&elq=3155b86a3ca045f0a2e27c182f392387&elqaid=7514&elqat=1&fbclid=IwAR1XYIdfEFpkUrdk-yTk6WKSvlsdncJBNrSy_OpdeuJhHXD2zi78WnxaSG8 XX Women with polycystic ovary syndrome (PCOS) were found to be at higher risk for developing type 2 diabetes over a 30-year period, according to new research presented at the 2022 American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo, and described in an article at Healio. PCOS is a hormonal disorder that causes enlarged ovaries containing small fluid-filled sacs, and it can have painful symptoms. Hormonal changes related to PCOS can also have effects throughout the body — including effects related to diabetes. One study estimated that nearly one in five adolescent girls with type 2 diabetes also has PCOS, although the nature of the link between PCOS and diabetes is still not fully understood. Many scientists believe, though, that insulin resistance — when tissues in the body become less sensitive to insulin, which is a large part of the disease process in type 2 diabetes — also plays a role in the development of PCOS. There is also evidence that correcting the hormonal imbalances seen in PCOS may reduce the risk of developing type 2 diabetes. A recent study showed that taking oral birth control pills as a treatment for PCOS reduced the risk for type 2 diabetes. https://www.diabetesselfmanagement.com/news-research/2022/11/16/polycystic-ovary-syndrome-linked-to-higher-risk-for-type-2-diabetes/ XX XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX SAFE TRAVELS to all en route to San Francisco for the Fall 2022 #Diabetes Mine #Innovation Days. Can't wait to see u all in person! Nov 17 and 18 XX XX On the podcast next week.. My daughter Lea talks about siblings and type 1. Last week was all about Eversense E3 and the future of long-term CGM sensors. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
Healio and BMC Ophthalmology say that patients with severe blindness and visual impairment admitted to American hospitals in 2017 had greater resource utilization and worse clinical outcomes than other patients. Why did this happen and what can we do about it? Study contributor Dr. Ché Matthew Harris from the John Hopkins School of Medicine is here to talk about the solutions to this issue and how our listeners might speak out to get the care they need and deserve. Ways to Connect to Speaking Out for the Blind Amazon Alexa enabled device (RECOMMENDED) “Alexa, Ask ACB Media to play Media 1”. (1 = stream number). PC / browser access (RECOMMENDED): Visit acbmedia.org at http://www.acbmedia.org/1 (1 = stream number). The site has a built-in media player and there is no need to install or use a media player on your device. Hit the play button and the stream will begin playing immediately. Smart device Access (RECOMMENDED): Download “ACB Link” from your app store. Find “Radio” along the bottom of the screen, then “Menu” in the top left corner. Select “Live Streams” and then choose “ACB Media 1 - Mainstream.” Double tap the play button. Victor Reader Stream Access: Navigate to “Internet radio library” in the “online bookshelf”. Locate the Humanware playlist. From the playlist, select ACB Media 1 (1 = stream number) and hit play. Alternate Dial-In access Dial 1 (518) 906-1820. Listen to the menu prompts and press 1. IMPORTANT NOTE The ACB Radio Tuner is no longer supported. If you used the tuner in the past, you may access all ACB Media streams from acbmedia.org (see above) If you are using alternate ways to access ACB Media streams than those above (such as Tune In or Winamp using acbradio.org URL's, we kindly ask that you use one of the methods above. Facebook page is at Speaking Out for the Blind and Twitter page is at SpeakOutfortheBlind (you may also access this at SpeakOutBlind). For more info related to this week's show, go to: https://speakingoutfortheblind.weebly.com/list-of-episodes-and-show-news/for-more-information-episode-303-hospitalizations-among-the-blind-and-visually-impaired
In this episode, Eleonora Teplinsky, MD, discusses the evolution of advocacy in the health care space, the challenges cancer patients face after the overturning of Roe v. Wade, and more. Disclaimer: The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of Healio. Welcome to another exciting episode of Oncology Overdrive :13 About Teplinsky :17 The interview: 1:07 How did you decide to do breast oncology, and how did you decide to incorporate advocacy into that space? 1:38 Have you seen an evolution in health care “advocacy”… and has it evolved over the years in how we engage in it? 4:47 Can you talk a little bit about these types of policy changes, how they're going to impact our patients? 8:59 How on earth could we say, “This is a medical emergency” and not be prosecuted for terminating the pregnancy in some of these states? 14:41 How can we call ourselves innovative, and forward-thinking, and breaking edge technology in health care and then make decisions that put us back hundreds of years? 16:32 What do we suggest to our colleagues, and patients, in these states if they find themselves in this situation? 20:37 When there is such massive disapproval for the reversal of Roe v. Wade, how do we move forward, and how do we make this change? 27:02 What do you do to keep pushing forward? How do you keep yourself engaged and motivated to try and make changes when it feels like nothing you're doing is actually making a difference? 27:59 Have you ever had a situation where somebody has come up to you in real life and said, “I didn't like what you put on social media”? Has a patient recognized you in a positive or negative way from something that you put out into the ethos of social media or beyond? 29:48 Let's say you had a magic wand, and you could wave it and make things exactly the way you want. What do you think needs to be done, specifically for the Roe v. Wade situation? … What would you think would be the best way to move forward? 32:43 If someone could only listen to the last 30 seconds of this podcast, what would you want them to take away? 34:37 How to contact Teplinsky 35:15 Thanks for listening 36:02 Eleonora Teplinsky, MD, is head of breast medical oncology at Valley-Mount Sinai Comprehensive Cancer Care; clinical assistant professor of medicine at The Icahn School of Medicine at Mount Sinai. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Teplinsky can be reached @drteplinsky on Twitter and Instagram, or at drteplinksy.com. Disclosures: Jain reports she is a paid freelance writer for Lippincott. Teplinsky reports no relevant financial disclosures.
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2022 ASCO Annual Meeting, as well as Healio's top headlines from the meeting. Stephen M. Ansell, MD, PhD, discusses efforts to identify new upfront treatment regimens to help extend OS in patients with relapsed or refractory classical Hodgkin lymphoma. :25 Lorenzo Cohen, PhD, shares his thought on the impact of acupuncture regimens on xerostomia and patients' quality of life. 5:26 Bradley J. Monk, MD, discusses the results of a study on the use of rucaparib monotherapy among women with advanced ovarian cancer 10:37 Christopher Manz, MD, MSHP, provides an overview of the results of the randomized PROStep trial, which assessed whether remote patient-reported symptoms and passive activity monitoring could improve patient-clinician communication about symptoms and functional status of patients with cancer. 18:09 Luke Maese, DO, discusses the results of the Children's Oncology Group AALL1931 study, its rationale, the potential implications of the findings and the questions that must be addressed in future research. 21:04 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20220603/firstline-brentuximab-vedotin-regimen-extends-os-in-advanced-classical-hodgkin-lymphoma https://www.healio.com/news/hematology-oncology/20220609/acupuncture-benefits-patients-with-radiationinduced-xerostomia https://www.healio.com/news/hematology-oncology/20220606/rucaparib-shows-efficacy-as-firstline-maintenance-therapy-in-ovarian-cancer https://www.healio.com/news/hematology-oncology/20220610/more-work-to-do-in-oncology-to-collect-useful-data-about-symptoms-functional-status https://www.healio.com/news/hematology-oncology/20220611/intramuscular-recombinant-erwinia-asparaginase-active-safe-in-leukemia-lymphoma-subsets Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset Source: Cercek A, et al. Abstract LBA5. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago. Trastuzumab deruxtecan extends survival in HER2-low metastatic breast cancer Source: Modi S, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago. Disclosures: Ansell reports research funding to his institution from ADC Therapeutics; Affimed Therapeutics, AI Therapeutics, Bristol Myers Squibb, Regeneron, Seagen and Trillium Therapeutics, and honoraria from Research to Practice and WebMD. Cohen reports no relevant financial disclosures. Monk reports relationships with Clovis Oncology, Merck, Roche/Genentech and several other pharmaceutical companies. Manz reports no relevant financial disclosures. Maese reports consultant and speakers bureau roles with Jazz Pharmaceuticals.
This week on Pharm5: AAPI patients underrepresented in clinical trials Camzyos (mavacamten) approved for obstructive HCM Voquenza (combination vonoprazan products) approved for H. pylori Pharmacy job postings up 18% in 2021 Implications of potential overturn of Roe v. Wade References: Asian, Indigenous, Latino patients underrepresented in US clinical trials of Biologics. Healio. https://www.healio.com/news/rheumatology/20211208/asian-indigenous-latino-patients-underrepresented-in-us-clinical-trials-of-biologics#:~:text=Asian%2C%20American%20Indian%2C%20Alaska%20Native,research%20letter%20published%20in%20JAMA. Accessed May 5, 2022. Camzyos Prescribing Information. accessdata.fda.gov. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214998. Accessed May 5, 2022. Cosdon N. FDA approves 2 vonoprazan treatments for helicobacter pylori infection. Contagion Live. https://www.contagionlive.com/view/fda-approves-2-vonoprazan-treatments-for-helicobacter-pylori-infection. Published May 3, 2022. Accessed May 5, 2022. Staff PT. FDA approves pair of Vonoprazan treatments for helicobacter pylori infection. Pharmacy Times. https://www.pharmacytimes.com/view/fda-approves-pair-of-vonoprazan-treatments-for-helicobacter-pylori-infection. Published May 4, 2022. Accessed May 5, 2022. Pharmacy Demand Report (PDR) 2021 Yearly Summary - aacp.org. https://www.aacp.org/sites/default/files/2022-04/pdr-2021-yearly-summary.pdf. Accessed May 5, 2022. Roe v. Wade live updates: Protests rage on over leaked abortion ruling. NBCNews.com. https://www.nbcnews.com/news/us-news/live-blog/roe-v-wade-live-updates-protests-rage-leaked-abortion-ruling-rcna27427. Published May 5, 2022. Accessed May 5, 2022.
'The only way to avoid a surgical complication is to not have surgery.' Yet, when they do happen, how do you navigate that conversation with your patients especially when you are not the surgeon that did the surgery. Dr. Anthony Romeo, is a Shoulder, Elbow, Sports Medicine surgeon at Duly Health and Care, Chief Medical Editor for Orthopedics Today at Healio, and the Executive Vice President of the Musculoskeletal Institute. His experience and reputation have made him a renowned surgeon for treating revisions and supporting secondary (or more) surgeries when there are original complications. In this podcast, he talks live with our host, Julie Soukup, about how to talk with patients when things DON'T go right in their surgery, and how to talk with a patient about complications. Not only when you are the surgeon that completed the work, but also when you are the revisionist surgeon.
In this podcast, Healio's John C. Carter, Chief Operating Officer and Joan-Marie Stiglich, ELS, Chief Content Officer, discuss the origins and future of Healio.
Meeting the needs of cancer program staff to ultimately improve patient outcomes is at the heart of the presidential themes of ACCC's current and immediate past presidents. CANCER BUZZ spoke to Krista Nelson, who advocated for the professional well-being of cancer program staff and Dr. David Penberthy, who aims to leverage technology to transform cancer care delivery and the patient experience. Hear how both tenures focus on what's most important in the cancer care community—supporting patients, clinicians, and staff. Krista Nelson, MSW, LCSW, OSW-C, FAOSWACCC 2021-2022 PresidentProgram Manager of Quality & Research, Cancer Support Services & CompassionProvidence Cancer InstitutePortland, OR David R. Penberthy, MD, MBAACCC 2022-23 PresidentMedical Director, Radiation Oncology, Bon Secours, Southside Regional Medical CenterPetersburg, VAResources: Krista Nelson's President's Theme 2021-22, "Real-World Lessons from COVID-19: Driving Oncology Care Forward.” Dr. David R. Penberthy's President's Theme 2022-23, “Leveraging Technology to Transform Cancer Care Delivery and the Patient Experience.” Making the Case for New Staff demonstrate the justification for hiring oncology supportive care staff.Mindfulness Meditations help members of the cancer care team better manage stress and improve their overall well-being.[MINI-PODCAST] Ep 74: The Business Case for Hiring Oncology Social Workers[Video] Dr. David R. Penberthy on Looking AheadNew Association of Community Cancer Centers president looks to technology-driven solutions, article from Healio.com[ACCCBuzz Blog] Recap: ACCC's 48th Annual Meeting and Cancer Center Business Summit Part 1 and Part 2
Episode 86: Abdominal Pain Case. Spikevax® is the brand name of the Moderna COVID-19, and it received full FDA approval in January 2022. Hepatitis B vaccine is now universally recommended to all adults between 19-59 years of age, or older than 60 with risk factors. Deidra Sieck presents a case of abdominal pain in pregnancy and differential diagnosis are discussed. Introduction: Spikevax ® and Hepatitis B universal vaccination. Written by Hector Arreaza, MD. Participation by Cecilia Covenas, MD.Spikevax®. This is the brand name given to the mRNA COVID-19 vaccine manufactured by Moderna. It was given full FDA approval for the prevention of COVID-19 in adults 18 years and older. This is the second vaccine approved by the FDA for the prevention of COVID-19 (the first vaccine was Comirnaty®, formerly known as Pfizer Vaccine.) The primary series of Spikevax for immunocompetent adults is comprised of 2 doses, 4 weeks apart. Immunocompromised patients receive a 3rd dose as part of the primary series, one month after the second dose. A booster shot of Spikevax is given at least 5 months after completing the primary series. Spikevax was also authorized for use as a “mix and match” single booster dose following completion of primary vaccination with a different COVID-19 vaccine. It means that recipients of the Pfizer and J&J vaccines who are 18 years and older may receive a single booster dose of Spikevax. The full FDA approval was granted to Spikevax on January 31, 2022.Did you know that Hepatitis B has killed 40 times more unvaccinated healthcare workers than HIV? Yes, that's right. Hepatitis B is 50 to 100 times more infectious than HIV. It is transmitted by percutaneous or mucosal exposure to infected blood or other bodily fluids. As a reminder, immunizations against many diseases have been required for health care workers for decades, and hepatitis B is one of those required vaccines. That's not new, what's new is the new recommendation about universal Hep B vaccination. In November 2021, the ACIP (Advisory Committee on Immunization Practices from CDC) recommended universal adult Hepatitis B vaccination. After reviewing clinical evidence, the ACIP has unanimously voted to recommend the Hep B vaccine for all adults ages 19-59. Patients who should receive hep B vaccines are: all adults between 19 and 59 years of age, and adults older than 60 with risk factors for hepatitis B infection. However, adults older than 60 without risk factors may also receive hep B vaccines. Vaccinating against Hep B is done to decrease new infections, prevent transmission, and reduce health disparities. HHS has called for the elimination of viral hepatitis as a public health threat by 2030. There are some reasons to recommend universal Hep B vaccination for adults: many infected patients did not have any risk factors for infection and still got infected; almost 85% of adults in the U.S. fall into a higher-risk group, including patients with diabetes and kidney disease; hepatitis B cases in the U.S. rose by 11% between 2014 and 2018 despite having highly effective vaccines; Hep B is one of the primary causes of liver cancer, one of the deadliest cancers; universal vaccination of newborns started in 1991 in the U.S., so, many adults are not immune to Hep B, but now they can be vaccinated without the many restrictions imposed in the past.Remember, Spikevax is the new name for the Moderna vaccine; and you can start vaccinating all adults between 19 and 59 years of age against hep B, regardless of risk factors.This is Rio Bravo qWeek, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California. Our program is affiliated with UCLA, and it's sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home.___________________________Abdominal Pain Case. By Deidra Sieck, MS4, Ross University School of Medicine. Hosted by Hector Arreaza, MD. Abdominal pain in pregnancy is quite common and has a wide differential. I want to begin with a case and then highlight a few of the “do-not-miss” diagnoses when a patient comes with the chief complaint of abdominal pain during her pregnancy. Case presentation: 23-year-old G2P1 at 32 weeks of gestation complains of 12 hours of right lower quadrant abdominal pain, anorexia, and nausea with vomiting. She denies vaginal bleeding or leakage of fluid from the vagina. Denies diarrhea or eating stale foods. No medical history and has been in good health. Denies dysuria and has had no previous surgeries. Her vital signs include a blood pressure of 100/70 mm Hg, heart rate of 105 beats per minute, and temperature of 101.5 F. On abdominal examination, bowel sounds are hypoactive. The abdomen is tender in the right lower quadrant to right flank with significant involuntary guarding. The cervix is closed. The fetal heart tones are in the range of 160 BMP (modified vignette from case files obstetrics and gynecology 5th ed.)What are some of the differentials that come to mind? The 6 differentials that should come to mind that are do not miss diagnoses include: Placental abruptionAppendicitis Cholecystitis Ectopic Pregnancy Hemorrhagic cyst Ovarian TorsionI want to discuss each of these diagnoses and then devise a plan for the patient in this case. Placental abruptionThis is the most common cause of third trimester bleeding and is an obstetric emergency. It occurs during the second and third trimesters and is described as a midline persistent suprapubic pain. The pain is also accompanied by vaginal bleeding as well as an abnormal fetal heart rate tracing. Mothers at risk have had a previous abruption, hypertension during the pregnancy, cocaine use, smoking, or preterm premature rupture of the membranes, or trauma as the most common cause of the abruption. This diagnosis is made clinically. The ultrasound is an unreliable modality to see the abruption. If the mother is stable and it is not a complete abruption, the mother usually delivers the baby very quickly vaginally. However, if the abruption is complete, the fetal heart tracing is category III, or the mother is hemodynamically unstable, it is best to deliver by c-section. Appendicitis. Appendicitis can occur any trimester during pregnancy and has been found to occur in 0.1-1.4/1000 pregnancies. The typical nonpregnant patient with appendicitis will come with complaints of right lower quadrant pain that may radiate to the right upper quadrant. This is usually associated with other complaints of nausea, vomiting, anorexia, or fever. [Anorexia: 80% sensitive, The sign of the hamburger] However, this diagnosis may be missed later in pregnancy because of an atypical presentation. As the gravid uterus grows, it can displace the appendix upward and lateral toward the flank. This leads to a presentation that appears to be more consistent with pyelonephritis, leading to a missed diagnosis. Because of the delay in diagnosis pregnant women are 2-3 times more likely to have a ruptured appendix, and the resulting peritonitis increases the likelihood of morbidity and mortality for the patient. If appendicitis progresses to appendiceal rupture, there is a 30% chance of spontaneous abortion of the fetus. These patients need an ultrasound to make the diagnosis since they cannot have a CT scan in pregnancy despite a CT scan being the preferred modality in nonpregnant patients. The ultrasound should show a non-compressible, blind-ended tubular structure in the right lower quadrant with a maximal diameter greater than 6mm.After the ultrasound confirms the diagnosis, these patients should be taken immediately for an appendectomy. However, the decreased resolution of imaging seen with ultrasound can also lead to delays in these patients receiving the appendectomy.Cholecystitis. Cholecystitis is more common in pregnancy, with occurrence in 1/1600 pregnancies. This can occur anytime in pregnancy after the first trimester. Pregnant women are especially high risk of cholecystitis since they are female and fertile. The other two “f's” that are commonly listed as risk factors for cholecystitis include forty, and obesity. [the F word is banned in this podcast]. Pathophysiology: The increased progesterone and estrogen increase bile lithogenicity. Progesterone also decreases gallbladder contractility. This increase in gallbladder volume and decreased contractility lead to an increase in “biliary sludge” in the gallbladder. The biliary sludge acts as a precursor to gallstones and obstruction of the cystic duct or the common bile duct. The patient with cholecystitis typically comes with complaints of pain in the right upper quadrant which can be associated with nausea, vomiting, anorexia, and fever. This is the same presentation as a patient in pregnancy. The complication of missing this diagnosis includes secondary infection with enteric flora such as: E. coli, Klebsiella, and Enterococcus faecalis. Fetal loss is seen in 3-20% of pregnancies complicated by cholecystitis. The diagnosis is made with a careful history as well as an ultrasound showing gallstones with dilation and thickening of the gallbladder and gallbladder wall. Treatment should be started with bowel rest, IV hydration, correction of electrolytes, analgesics. They should be given antibiotics if no improvement after 12-24 hours or are experiencing systemic symptoms. If the medical management does not work, these patients should have a cholecystectomy. The cholecystectomy will most likely be laparoscopic due to the gravid uterus making it difficult to perform an open approach. If in the third trimester and the patient is stable, the surgeon may opt to wait until after delivery to remove the gallbladder.Ectopic pregnancy. This is the leading cause of maternal mortality in the first and second trimesters. It usually presents during the first trimester as pelvic or abdominal pain that is usually unilateral. The patient could also complain of nausea, vomiting, syncope, or vaginal spotting. The diagnosis is made using a serum hCG that meets the threshold and transvaginal ultrasound. The treatment can be surgical or medical. If the pregnancy is early, methotrexate can be used. However, the hCG needs to be trended and followed to zero. A D&C can also be used to treat ectopic pregnancy. Surgery is the first treatment in a patient that is hemodynamically unstable. This diagnosis is not likely in our patient.Ruptured corpus luteum or ruptured hemorrhagic cyst. The corpus luteum cyst is part of a normal endocrine function or a result of prolonged progesterone. In pregnancy, the corpus luteum produces progesterone until 7-10 weeks' gestation until the placenta can produce steroids including hCG and progesterone to maintain the pregnancy. However, intrafollicular bleeding can occur because of the thin-walled capillaries that invade the granulosa cells from the theca interna. If there is excessive hemorrhage, the cyst can enlarge and rupture. The patients presenting with this complaint present with unilateral cramping and lower abdominal pain 1-2 weeks before the rupture. If the corpus luteum becomes hemorrhagic, a hemoperitoneum can develop. These women should undergo an ultrasound, which will show free intraperitoneal fluid. This could also include some fluid around the ovary. The confirmatory method for diagnosis is laparoscopy. Culdocentesis is a procedure that checks for abnormal fluid in the space just behind the vagina. This area is called the cul-de-sac. During a culdocentesis, a long thin needle is inserted through the vaginal wall just below the uterus and a sample is taken of the fluid within the abdominal cavity.Once the bleeding is controlled, there is no further treatment needed. However, if the patient requires a cystectomy due to continued bleeding and the pregnancy is less than 10 weeks, she will need exogenous progesterone because of the loss of the corpus luteum. Ovarian Torsion. Pregnancy is a risk factor for ovarian torsion, especially around 14 weeks and after delivery. Torsion is most likely between 10-17 weeks, and more likely to happen in masses 6-8 cm in diameter. Pregnant and nonpregnant patients have the same presentation, suprapubic or lower quadrant pain, nausea, and vomiting, up to 20% can have a fever. Plan for the patient in the case:1. Ultrasound: Showed a non-compressible, blind-ended tubular structure in the right lower quadrant with a maximal diameter of 7mm.2. Appendectomy: Take the patient to the OR.____________________________Now we conclude our episode number 86 “Abdominal Pain Case.” We started by giving you an update on Spikevax®, formerly known as “the Moderna vaccine”. This is the newest COVID-19 vaccine fully approved by the FDA for patients 18 years and older. Also, Hepatitis B vaccination is now recommended universally to all adults 19-59 regardless of risk factors. Then, Deidra presented a case of a patient who was pregnant and had abdominal pain. Surprisingly, her diagnosis was appendicitis. This is a good reminder that pregnant and nonpregnant patients can get appendicitis. Even without trying, every night you go to bed being a little wiser.Thanks for listening to Rio Bravo qWeek. If you have any feedback about this podcast, contact us by email RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. This podcast was created for educational purposes only. Visit your primary care physician for additional medical advice. This week we thank Hector Arreaza, Cecilia Covenas, and Deidra Sieck. Audio edition: Suraj Amrutia. See you next week! _____________________References:Coronavirus (COVID-19) Update: FDA Takes Key Action by Approving Second COVID-19 Vaccine, US Food and Drug Administration, January 31, 2022. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine. ACIP fully recommends Spikevax, as CDC expands wastewater surveillance, University of Minnesota, Center for Infectious Disease Research and Policy (CIDRAP), February 04, 2022. https://www.cidrap.umn.edu/news-perspective/2022/02/acip-fully-recommends-spikevax-cdc-expands-wastewater-surveillance. ACIP recommends universal hepatitis B vaccination for adults aged 19 to 59 years, Healio.com, https://www.healio.com/news/infectious-disease/20211103/acip-recommends-universal-hepatitis-b-vaccination-for-adults-aged-19-to-59-years. Landmark vote by CDC's Advisory Committee on Immunization Practices (ACIP) to recommend universal hepatitis B vaccination, Hepatitis B Foundation, November 4, 2021. https://www.hepb.org/news-and-events/news-2/the-cdcs-advisory-committee-on-immunization-practices-acip-voted-to-recommend-universal-hepatitis-b-vaccination/ Ananth, Cande Vanessa V, and Wendy L Kinzler. “Placental Abruption: Pathophysiology, Clinical Features, Diagnosis, and Consequences.” Edited by Charles J Lockwood, and Vanessa A Barss, 22 Feb. 2021, https://www.uptodate.com/contents/placental-abruption-pathophysiology-clinical-features-diagnosis-and-consequences. Brooks, David C. Edited by Stanley W Ashley et al., Gallstone Disease in Pregnancy, 26 July 2021, https://www.uptodate.com/contents/gallstone-diseases-in-pregnancy. H., De Cherney Alan, et al. “Chapter 25: Surgical Disorders In Pregnancy.” Current Diagnosis and Treatment: Obstetrics and Gynecology, McGraw Hill Medical Publishing Division, 2019. “Obstetrics and Gynecology.” Case Files: Obstetrics and Gynecology 5th Edition, by Eugene C. Toy et al., McGraw-Hill Medical, 2016, pp. 135–144. Rebarber, Andrei, et al. “Acute Appendicitis in Pregnancy.” Edited by Martin Weiser et al., Up To Date , 17 Sept. 2021, https://www.uptodate.com/contents/acute-appendicitis-in-pregnancy. Runowicz, Carolyn D, and Molly Brewer. “Adnexal Mass in Pregnancy.” Edited by Barbara Goff and Alana Chakrabarti, UpToDate, 10 Feb. 2022, https://www.uptodate.com/contents/adnexal-mass-in-pregnancy. Tulandi, Togas. “Ectopic Pregnancy: Clinical Manifestations and Diagnosis.” Edited by Deborah Levine et al., UpToDate, 18 Jan. 2022, https://www.uptodate.com/contents/ectopic-pregnancy-clinical-manifestations-and-diagnosis.
In this episode, hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news in eyecare, then speak with Eric Rosenberg, DO, about the current state and future of digital ophthalmology. Intro :10 Brief recap of episode 2 with Nicole Fram :55 News and Notes 1:31 Generic of Allergan's Restasis by Mylan Pharmaceuticals and discussion of generics in the ophthalmic space 2:05 Aramis Biosciences in phase 2 neuromodulator dry eye program and discussion of dry eye 5:12 Jim discusses Aetna's prior authorization for cataract surgery 6:54 Bilateral same day cataract surgery discussion 8:48 Eric Rosenberg, DO, introduction 10:48 What is digital? What is the meaning of digital? 11:38 Goals of the Digital Ophthalmic Society 17:33 Barriers to adoption of digital 22:34 What will DOS be discussing at Eyecelerator@ASCRS? 23:56 What Rosenberg hopes the DOS will achieve in the future 27:38 Thank you, Eric 29:42 Roger Ohanesian to receive Chang/Crandall Humanitarian Award at ASCRS 30:01 Sneak peek at the next episode 32:18 For more information: John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Eric Rosenberg, DO, is a cornea, cataract, and refractive surgeon at SightMD. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Rosenberg via email at ericr29@gmail.com. To learn more about the DOS, visit: https://www.digitalophthalmicsociety.com/. Disclosures: Hovanesian consults widely in the ophthalmic field and specifically with Alcon, Ivantis and Sight Sciences. Mazzo reports being an adviser for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Centricity Vision, Crystilex, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Rosenberg at the time of publication.
In this episode, Cassandra Calabrese, DO, dual-boarded in infectious disease and rheumatology, walks us through when to suspect Bartonella (it's not always a house cat!), how to diagnose and how to treat. Intro :01 Welcome to another exciting episode of Rheuminations :11 About today's episode :17 10th Annual Basic and Clinical Immunology for Busy Clinicians starts 2/26 2:18 A look at upcoming episodes 3:00 Check out Healio's Rheum + Boards – new questions coming soon! 3:15 The interview with Dr. Cassandra Calabrese 4:08 Is there always a cat exposure? 5:19 Are there other animals to look out for? Or other scenarios? 6:15 Endocarditis and Bartonella – consider these when things aren't adding up 7:20 What about Bartonella quintana, do you always treat it? 9:43 It seems Bartonella can be more subtle than other infectious endocarditis, is that true? 10:49 When suspicious, how do we test for Bartonella? 11:57 Titer is important 13:57 How do you treat this? 14:43 What are long-term outcomes like? 16:38 Thank you, Dr. Calabrese 17:35 Warthan-Starry stain 17:54 Thanks for listening 21:24 Cassandra Calabrese, DO, is associate staff in the department of rheumatic and immunologic disease and the department of infectious disease at Cleveland Clinic Foundation. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum Disclosures: Brown and Calabrese report no relevant financial disclosures. References: Wright JR. Arch Pathol Lab Med. 2021;145:1297-1306.
Nicole Fram, MD, MPH, is a wearer of many hats and seems to be able to wear them all well. In this episode, she sits down with hosts, Jim Mazzo and John A. Hovanesian, MD, FACS, to discuss taking over as managing partner for Advanced Vision Care and Samuel Masket, MD, balancing her many professional roles, and shares her point of view on new and upcoming products and technologies in eye care. Welcome to the Eyeluminaries podcast :10 News and notes with John and Jim 1:07 Alcon completes acquisition of Ivantis 1:11 FDA approves Genentech's Vabysmo for AMD, DME 3:54 Sight Science's TearCare system for MGD receives 510(k) clearance 6:32 About Nicole Fram 9:54 The interview 11:23 What is it like to take over a practice from Sam Masket? 13:02 Being a mom who is running a practice, sitting on boards, being an OSN section editor now, and chairing or sitting on all these committees, how on earth do you do it all, Nicole? 15:51 Are you getting better at saying no to some things? 18:05 I know COVID made us kind of rethink everything, which included meetings. But what do you think the future of these meetings are? 19:32 What do you think about the way this market is going to evolve? How is pilocarpine going to compete with some of these other products? And how do we differentiate between these different offerings? 22:39 How are you deciding which companies' technologies you decide to spend your very valuable time on? 29:25 What do you think about the ICA lens? Is that going to take some of what you used to do with LALs? Where's that going to fit in potentially? 31:53 Thank you, Nicole Fram 36:12 Thanks for listening 36:50 Nicole Fram, MD, is the managing partner of Advanced Vision Care and a clinical instructor of ophthalmology at the Stein Eye Institute, University of California, Los Angeles. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Fram on Twitter @NicoleFramMD. Disclosures: Hovanesian consults widely in the ophthalmic field and specifically with Alcon, Ivantis and Sight Sciences, who are discussed in this episode. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Healio could not confirm relevant financial disclosures for Fram at the time of publication.
In each episode, your hosts John A. Hovanesian, MD, and Jim Mazzo explore the latest news and trends with newsmakers and visionaries in eye care. Hovanesian is OSN Associate Medical Editor and in private practice at Harvard Eye Associates in Laguna Beach, California Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss Meditec and AMO.
In this episode, Joel M. Gelfand, MD, MSCE, is joined by Leonard H. Calabrese, DO, and Amesh Adalja, MD, FIDSA, as they discuss quarantine and isolation guidelines, emerging therapies to treat COVID-19, and the anticipated future of the COVID-19 pandemic. Welcome from Joel Gelfand, MD, MSCE :10 About Calabrese and Adalja :11 At day five, what's your recommendation for clinicians how to counsel people about testing to get out of isolation? Do you recommend people go ahead and get tested to end isolation or to just end isolation if not having much symptoms or improving? :51 How should we counsel our immunocompromised patients? Should they really isolate for 20 days? 5:21 Can people continue to test positive and antigen test beyond the infectious period? 10:13 In the clinical setting, you know, should physicians be wearing N95 masks, and if so, what's that databased on? 15:22 If a person has a positive antigen test but a negative PCR on the same day, how do you interpret that information for a patient? 22:12 Now we finally have emergence of effective therapies for people with COVID-19. How do you think about these different therapies? Do you have an algorithm that you'd recommend to clinicians in the field about which one to reach for first? 24:05 When someone has a COVID infection how soon thereafter can you give them a COVID immunization? 27:47 With Omicron working its way through the US and obviously through the world, where do you see the next three to six months going? 28:34 Thank you everyone 31:29 Amesh Adalja, MD, FIDSA,is senior scholar at Johns Hopkins and a practicing infectious disease and critical care physician in Pittsburgh. Leonard H. Calabrese, DO, is chief medical editor of Healio Rheumatology, professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer Chair of Clinical Immunology at the Cleveland Clinic. Joel M. Gelfand, MD, MSCE, is chief medical editor of Healio Psoriatic Disease and professor of dermatology and epidemiology at the Perelman School of Medicine at the University of Pennsylvania. He is also vice chair of clinical research, medical director at the Dermatology Clinical Studies Unit, and director of the Psoriasis and Phototherapy Treatment Center at Penn Medicine. We'd love to hear from you! Send your comments/questions to Dr. Gelfand, Calabrese and Adalja at covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews, @GoHealio, @DrJoelGelfand, @LCalabreseDO and @AmeshAA. Disclosures: Adalja reports no relevant financial disclosures. Calabrese reports consulting for AstraZeneca, GSK and Regeneron. Gelfand reports serving as a consultant for Abcentra, Abbvie, BMS, Boehringer Ingelheim, GSK, Lilly (DMC), Janssen Biologics, Novartis Corp, UCB (DSMB), Neuroderm (DSMB), Trevi, and Mindera Dx., receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Boehringer Ingelheim, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly pharmaceutical sponsors. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma. Gelfand is a deputy editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology, is chief medical editor for Healio Psoriatic Disease (receiving honoraria) and is a member of the Board of Directors for the International Psoriasis Council, receiving no honoraria.
In this episode, Joel M. Gelfand, MD, MSCE, and Leonard H. Calabrese, DO, are joined by Paul E. Sax, MD, as they discuss advances in the outpatient management of COVID-19 and emerging information about the omicron variant. Welcome from Joel Gelfand, MD, MSCE :10 About Calabrese, Gelfand and Sax :25 A quick update since the last webinar :51 Sax's thoughts on the effectiveness of monoclonal antibodies 1:46 What are the situations where we should be thinking about postexposure prophylaxis with these agents? 7:06 When you start using pre-exposure prophylaxis therapy, how would you counsel the patients receiving it? 12:56 How does Merck's molnupiravir work? 17:22 Sax's thoughts on Pfizer's paxlovid 22:23 What's your perspective on fluvoxamine? Does it work? 25:26 Paul, what have you learned so far about the omicron variant? 30:15 How much more contagious is this than Delta and what would you compare it to? 31:09 Questions from the audience 35:27 Tweet your questions @DrJoelGelfand, @LCalabreseDO and @PaulSaxMD. 38:35 Leonard H. Calabrese, DO, is chief medical editor of Healio Rheumatology, professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer Chair of Clinical Immunology at the Cleveland Clinic. Joel M. Gelfand, MD, MSCE, is chief medical editor of Healio Psoriatic Disease and professor of dermatology and epidemiology at the Perelman School of Medicine at the University of Pennsylvania. He is also vice chair of clinical research, medical director at the Dermatology Clinical Studies Unit, and director of the Psoriasis and Phototherapy Treatment Center at Penn Medicine. Paul E. Sax, MD, is clinical director of the Infectious Disease Clinic and professor of medicine at Harvard Medical School. We'd love to hear from you! Send your comments/questions to Drs. Gelfand, Calabrese and Sax at covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews, @GoHealio, @DrJoelGelfand, @LCalabreseDO and @PaulSaxMD. Disclosures: Calabrese reports consulting for AstraZeneca, GSK and Regeneron. Gelfand and Sax report no relevant financial disclosures.
Bartonella is an important mimic of a variety of autoimmune diseases, and it can be subtle. This episode tackles the ways in which this strange organism can present to a rheumatologist. Brought to you by Genentech Intro :01 Today's episode :15 Overview of Bartonella 1:57 Inspiration for this episode 4:17 Bartonella, what are you? 7:24 About Bartonella quintana 12:32 Take-away so far 16:07 Core symptoms and rheumatologic aspects 17:15 About serologies 24:51 Key takeaways from this episode 28:09 Check out Rheum + Boards on Healio at com/rheumandboards 28:31 Disclosure: Brown reports no relevant financial disclosures. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum and be sure to check out Rheum + Boards – your destination for rheumatology education and quizzes! References: Aslangul E, et al. J Rheumatol. 2014;doi:10.3899/jrheum.130150. Beydon M, et al. Rheumatology (Oxford). 2021;doi:10.1093/rheumatology/keab691. Im JH, et al. Vector Borne Zoonotic Dis. 2018;18:291-296. Jacobs RF, Schutze GE. Clin Infect Dis. 1998;26:80-84. Maman E, et al. Clin Infect Dis. 2007;45:1535-1540. Raybould JE, et al. Infect Dis Clin Pract (Baltimore). 2016;24:254-260. Zangwill KM, et al. N Engl J Med. 1993;329:8-13.
This is the first in a series of town halls featuring Joel M. Gelfand, MD, MSCE, and Leonard H. Calabrese, DO, who will discuss the latest knowledge and research on COVID-19. In this episode, they're joined by Carlos del Rio, MD, who discusses the use of booster shots in the general population and in patients with underlying autoimmunity. Welcome from Joel Gelfand, MD, MSCE :10 About Calabrese, del Rio and Gelfand :30 del Rio on the future of the pandemic 1:12 Recommendations for boosters in general population 3:25 What does “immunocompromised” mean in terms of boosters? 6:14 What is an additional dose vs. booster dose? Who's eligible? 9:24 Summary 14:12 Immunosuppressed patients – degree of severity 16:14 Safety of boosters in general population 17:00 Safety of boosters in those with underlying autoimmunity 18:12 Questions from the audience 22:03 Tweet your questions @DrJoelGelfand, @LCalabreseDO and @CarlosdelRio7 29:24 We'd love to hear from you! Send your comments/questions to Drs. Gelfand, Calabrese and del Rio at covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews, @GoHealio, @DrJoelGelfand, @LCalabreseDO and @CarlosdelRio7.
In this podcast, Healio's Andrea Gaymon, Chief Product Officer and Matthew Dechen, Vice President, Deep Engagement and Custom Solutions, discuss how good product design and usability are essential today in delivering online engagements and supporting HCP education.
In this episode, the third of a three-part series, John B. Pinto discusses some of the future megatrends expected for ophthalmic practices, challenge practices may face in the future, and more. Intro :13 What you think the megatrends are going to be over the next decade or so in the ophthalmic practices :50 What do you think is the most important topic or issue or challenge facing ophthalmic practices now and in the future? 4:46 If our listeners wanted to learn more, what's the best way to contact you? 10:02 I really appreciate you and all your great advice 10:47 Any final words? 11:00 Thank you so much John, I appreciate it 11:16 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto's Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.
What is Paget's? Why is it declining across much of the globe? Find out, plus hear an interview with the head of the center for osteoporosis and metabolic bone disease at Cleveland Clinic, Chad Deal, MD. Brought to you by GSK. Intro :11 Today's episode :27 What is Paget's? 1:07 The history of Paget's 5:35 How often is this symptomatic? 9:30 The epidemiology of Paget's 13:22 The data on viruses and Paget's disease 21:08 An interview with Dr. Chad Deal25:09 The numbers are showing a decline in Paget's disease, are you seeing that? 26:03 Identifying Paget's disease … who's picking this up? 27:01 Can you walk us through those studies again? 27:58 Can you tell us a little bit about hypervascularity found in these patients? 30:32 Can you walk us through the history of how the treatments have changed? 31:37 Paget's kind of just doesn't go anywhere … is that what you've seen in your practice? 35:05 What if the patient has poor or borderline kidney function? Do they have other options? 37:07 Have you seen familial cases? Are people more prone to get it if someone in the family has it? 38:32 A discussion on osteosarcoma 39:55 Dr. Deal, thank you so much for your time and your knowledge about metabolic bone 42:46 Episode summary 42:52 I hope you learned something and thanks for listening! 44:47 Disclosure: Brown reports no relevant financial disclosures. Healio was unable to confirm relevant financial disclosures for Deal at the time of publication. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum References: Cundy T. Metabolism. 2018;80:5-14. Haddaway MJ, et al. Br J Radiol. 2007;80:523-526. Poór G, et al. J Bone Miner Res. 2006;21:1545-1549. Renier JC, Audran M. Rev Rhum Engl Ed. 1997;64:35-43. Shaw B, et al. Proc Natl Acad Sci USA. 2019;10463-10472. Singer FR. Nat Rev Endocrinol. 2015;11:662-671. Wermers RA, et al. J Bone Miner Res. 2008;23:819-825. Music by Lesfm from Pixabay.
In this second episode of a three-part series, John B. Pinto discusses the job market for early-career professionals and new graduates, his perspective on what ophthalmologists have learned from the pandemic and the role telemedicine will play in the future of ophthalmology. Intro :14 What is the current negotiation position in the market for early-career and new graduate ophthalmic practice physicians? :41 I'd love to hear your perspective on what we have learned about our practices after a year of this pandemic 3:35 How is the telemedicine trend going now? Is telemedicine here to stay? 11:09 Tell us about your upcoming book and your insight into it? 12:59 Stay tuned for the next episode of this special three-part miniseries 17:38 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto's Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.
This week, the ATS issued a new clinical practice guideline for noninfluenza viral pathogen testing in community-acquired pneumonia; the FDA issued two approvals: the first new Alzheimer's treatment since 2003, as well as once-weekly semaglutide for weight loss; and Healio spoke with experts regarding the use of face masks among children, and the link between COVID-19 vaccination and tinnitus.
In this episode, the first of a three-part series, John B. Pinto discusses how he got started in ophthalmic practice management, shares an historical perspective on the field, plus his advice for physicians. Intro :16 About John Pinto :54 On Pinto's background, why he went into the ophthalmic practice management industry 1:39 Can you give listeners a historical perspective of how has ophthalmic practice management changed or evolved over the last 40 years? 7:13 What is the current state of ophthalmic practice management in America today? 13:11 Could you give a key pearl for how to handle practice management as an early- or mid-career physician as well as a late-career/ retirement-age physician? 16:02 In your experience, what would you say would be the average age of full retirement in ophthalmology? 23:56 Stay tuned for the next episode of this special three-part miniseries 27:19 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto's Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.
In this episode of Meeting Mic, we bring you pearls and perspectives from the American Thoracic Society 2021 International Conference, as well as Healio's top headlines from the virtual meeting. Leonard Bacharier, MD, discusses results of the VOYAGE study of dupilumab in children with asthma :35 Dennis Hwang, MD, shares data from a study that looked at severe obstructive sleep apnea and COVID-19 risk 7:11 Alayna Tackett, PhD, discusses results of her analysis of e-cigarette use and the association with wheeze and shortness of breath, even in young adults who don't smoke 10:25 Michael Wechsler, MD, shares data from the LIBERTY ASTHMA TRAVERSE Extension Study, which assessed long-term maintenance of oral corticosteroid reduction and efficacy with dupilumab in patients with asthma 14:01 Ana Hernandez Cordero, PhD, discusses data from an integrative genomic analysis of potential genetic risk factors for COVID-19 23:15 Read the full coverage here: https://www.healio.com/news/pulmonology/20210519/tezepelumab-reduces-exacerbations-in-broad-population-of-patients-with-severe-asthma https://www.healio.com/news/pulmonology/20210518/multiple-disease-progression-events-less-likely-with-continued-inhaled-treprostinil https://www.healio.com/news/pulmonology/20210517/monoclonal-antibody-cocktail-cut-covid19-hospitalization-death-by-70-in-outpatient-setting https://www.healio.com/news/pulmonology/20210516/fauci-covid19-vaccines-the-bright-light-of-this-extraordinary-challenge Disclosures: Bacharier reports he received speaker fees from AstraZeneca, GlaxoSmithKline, Regeneron and Sanofi; was on the data safety monitoring board for Cystic Fibrosis Foundation and DBV Technologies; and received research support from NIH, Sanofi and Vectura. Hernandez Cortez reports funding from MITACS and Providence Health Center. Hwang reports that efforts for the study were supported by grants from the American Academy of Sleep Medicine Foundation and from internal Kaiser research support. Tackett reports no relevant financial disclosures. The research was supported by the National Heart Lung and Blood Institute from the NIH and the Oklahoma Tobacco Settlement Endowment Trust. Wechsler reports he received consultant fees from AstraZeneca, Amgen, Boehringer Ingelheim, Cohero Health, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi, Sentien and Teva.
In this episode, psychiatrist Michael F. Myers, MD, discusses the use of couples therapy in households comprised of single- and dual-physician families, the rate of depression among members of the medical field, and more. Intro :13 About Myers :18 The interview 1:27 How did you get into the field of psychiatry? How did you end up in a space with such a specialized area of expertise? 1:44 Have you noticed there’s a big difference in those different family dynamics between families with single-physician households and dual-physician households in those types of patients that you treat? 5:21 You actually decided in your career to also include couples therapy … how did you decide to incorporate it into your practice? 10:03 Have you found that the rate of depression among medical students, doctors is higher than the general population? Why are we seeing these high rates of depression? 14:20 How do we continue to move the needle against these stigmas of mental illness among medical health professionals? 18:16 Have you noticed more suicides among students and residents? Have you been asked to talk to people in that space? Is there something we can do to help support students and residents? 25:58 What has it been like in this last year in taking care of doctors? Has your practice changed at all and have you noticed things are different this year? 33:29 If someone could only listen to the last two minutes of this episode what would you want them to take away? 39:21 Where can people purchase your book, “Becoming a Doctor’s Doctor,” and how can people find you if they want to connect with you? 40:11 Michael F. Myers, MD, is professor of clinical psychiatry and recent past vice-chair of education and director of training in the Department of Psychiatry & Behavioral Sciences at SUNY-Downstate Health Sciences University in Brooklyn, NY. He is also the author of “Becoming a Doctor’s Doctor.” We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday @ShikhaJainMD. Dr. Myers can be reached at his website, www.michaelfmyers.com, on Twitter @downstatedoctor and on Linkedin. Disclosures: Jain reports she is a paid freelance writer for Lippincott. Healio was unable to confirm relevant financial disclosures for Myers at the time of publication.
Coming soon, from Healio, Vital Capacity - a pulmonary and critical care podcast bringing you clinical pearls and insight from experts in the field, plus the top headlines. Be sure to subscribe for episode alerts, and follow us on twitter @HealioPulm.
Healio's Zach Gursky and Matt Holland sit down with MM+M's Larry Dobrow to discuss the evolution of ad-tech amid COVID-19.
Behavior change intervention aimed at increasing physical activity improves asthma control - Celso R. F. Carvalho Behavior change intervention aimed at increasing physical activity improves asthma control ADD TOPIC TO EMAIL ALERTS A comprehensive behavior change intervention aimed at increasing physical activity yielded improvements in clinical control, sedentary time, sleep quality and anxiety in adults with moderate to severe asthma. “Exercise-induced asthma occurs in 60 to 70% of asthmatics, then, they avoid participating in sports or physical activities. Our study aimed to evaluate if improving physical activity (low to moderate-intensity exercise) could turn subjects healthier and improve asthma symptoms,” Celso R.F. Carvalho, PhD, associate professor at the School of Medicine at the University of São Paulo, told Healio. The single-blind, randomized controlled trial enrolled 51 participants with moderate to severe asthma. Participants were randomly allocated to the behavioral change intervention group (n = 25; mean age, 46.4 years; 80% women) or a control group (n = 26; mean age, 45.9 years; 88% women). Both groups received usual care and disease-specific education. Those in the intervention group underwent an 8-week behavior change intervention with the goal of increasing physical activity. Participants attended weekly 40-minute counseling sessions focused on behavior change techniques to increase physical activity, including setting goals, feedback and information on health consequences; received a workbook and a wearable device to review data; and established an individualized action plan. The researchers obtained asthma exacerbation data 12 months prior and throughout the intervention period and measured asthma control, physical activity, sedentary time, sleep quality, health-related quality of life, and anxiety and depression symptoms before and after the intervention period. Participants in the intervention group demonstrated improvements in asthma control (mean difference, –0.8; 95% CI, –1.1 to –0.4), daily step count (mean difference, 3,605; 95% CI, 1,937-8,867), sleep efficiency (mean difference, 9.2%; 95% CI, –7.1 to 21.9) and reduced sedentary time (–1.1 hours per day; 95% CI, –2.9 to –0.6). Compared with 60% of participants in the control group, 27% of participants in the intervention group experienced asthma exacerbations during the intervention period (P = .04). The researchers reported an inverse association with change in time spent in moderate-intensity physical activity and change in asthma control (r = 0.6). A larger percentage of patients in the intervention group reported a reduction in anxiety symptoms (43% vs. 0%; P < .02). Researchers observed no difference in health-related quality of life between both groups. “Our study provides important evidence that increasing physical activity in daily life can lead to an improvement in asthma control,” Carvalho said. “The next step will be increasing the number of subjects and evaluating long-term benefits.” For more information: Celso R. F. Carvalho, PhD, can be reached at cscarval@usp.br.
Rachel Solnick, MD, MSc, is an emergency medicine physician and health services researcher. In this episode, we discuss her journey into public policy, how to navigate through medical misinformation on social media and why doctors should be policy advocates. Intro :14 About Solnick :16 The interview 1:10 How did you become an ER physician focusing on policy and research? What was your journey to get to this point in your career? 1:13 Did you start this research policy fellowship before the pandemic? 3:37 How did this whole process start on writing your study and what were the results? 4:48 How did you set up the study? 9:50 What did you find? 13:30 Do you think that the messenger is just as important? 14:37 What’s your opinion on people who put information out there that’s factually inaccurate? How can people get through the noise? 18:09 Have you found that the way you’ve interacted on social media has changed over the last year throughout the pandemic? 19:37 Why should we as doctors be advocates and why should we be working on policy? 23:20 How has it been like being a physician clinically during this time? 31:53 Solnick’s one pearl of wisdom 35:10 Where to find Solnick? 36:05 Rachel Solnick, MD, MSc, is an emergency medicine physician and health services researcher. She is currently a second year National Clinical Scholars Program research fellow and practicing physician at the University of Michigan Emergency Department and the Institute for Healthcare Policy and Innovation. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Rachel Solnick can be reached on Twitter @RachelSolnickMD. Follow us on Twitter @HemOncToday @ShikhaJainMD. Disclosures: Jain reports she is a paid freelance writer for Lippincott. Healio was unable to determine relevant financial disclosures for Solnick at the time of publication.
Patricia W. Finn, MD, is a physician scientist focusing on the microbiome and immune-mediated pulmonary diseases. In this episode, she shares her experiences in health care, effects of the pandemic and the importance of personal care. Intro :14 About Finn :30 The interview 2:17 Can you tell us a little bit about your journey? 2:37 Were there things in your career path that led you to feeling like you needed to do more for those who might be marginalized or might face challenges similar to what you faced? 8:40 How have you seen the emotional impact of the pandemic manifest in the health care systems and how have you helped people manage or deal with that? 21:39 Has the way this pandemic has ebbed and flowed changed the way you’ve approached things? 28:26 When all is said and done, do you think we’ll leave this pandemic with some positive changes to the health care system as a whole? 33:40 Some of the positive innovations that have come from the pandemic 37:40 Finn’s one pearl 44:35 How to contact Finn 45:24 Patricia W. Finn, MD, is the Earl M. Bane professor chair and head of the department of medicine and the associate dean for strategic initiatives and an associate program director for the medical scientist training program at the University of Illinois at Chicago. She is a physician scientist focusing on the microbiome and immune-mediated pulmonary diseases including sarcoidosis, transplantation, lung injury and asthma. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Finn can be reached by email at pwfinn@uic.edu. Follow us on Twitter @HemOncToday @ShikhaJainMD. Disclosures: Jain reports she is a paid freelance writer for Lippincott. Healio was unable to determine relevant financial disclosures for Finn at the time of publication.
In this podcast episode, we interview Barry Marshall, AC, FRACP, FRS, FAA, the legendary Nobel Laureate who discovered that peptic ulcer disease was caused by the bacteria Helicobacter pylori, not excess acid. Marshall fought for years against the notion that ulcers were caused by acid and finally infected himself with the bacteria and underwent endoscopy to prove his point. His research has saved countless lives, as untreated ulcer disease can lead to gastric cancer. We discuss numerous facets of his life and his pioneering work. Before antimicrobial therapy against Helicobacter, patients suffered for years without the right therapy. Brought to you by Redhill Biopharma, makers of Talicia (omeprazole magnesium, amoxicillin and rifabutin) delayed release capsules. Visit talicia.com for more information, including full prescribing information. Intro :35 About Dr. Marshall :37 The interview 3:30 Tell us about your upbringing. What was your childhood like? 3:38 How did you meet Robin Warren? 6:35 What was your ah-ha moment that made you want to follow it through? 13:11 Brought to you by Redhill Biopharma, makers of Talicia (omeprazole magnesium, amoxicillin and rifabutin) delayed release capsules. Visit talicia.com for more information, including full prescribing information. 40:56 Were you met with skepticism? 41:13 How did you interact with the naysayers at the time? 51:46 What drove you to infect yourself with H. pylori? 1:01:28 What was it like to win the Nobel prize? 1:10:14 What advice do you have for young faculty members or GI fellows embarking on an investigative career? 1:18:18 Thank you, Dr. Marshall 1:22:30 Barry Marshall, AC, FRACP, FRS, FAA, is an Australian physician, Nobel Prize Laureate in Physiology or Medicine, and professor of clinical microbiology at the University of Western Australia. We’d love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on Twitter @HealioGastro @sameerkberry @umfoodoc Disclosures: Berry and Chey report no relevant financial disclosures. Healio was unable to confirm relevant financial disclosures for Marshall at the time of publication.
Researchers and regulatory agencies are racing against the clock to develop a safe and effective vaccine against COVID-19. This episode outlines the path of vaccine development, the top contenders currently in phase 3 trials, as well as questions that remain unanswered. Intro :08 The path of vaccine development 2:55 Regulatory agencies working on a vaccine 4:09 The lifecycle of vaccines 7:43 Potential targets of the vaccines 10:58 Top contenders in phase 3 trials 14:13 Viral vector vaccines 21:03 Protein-based vaccines 23:31 Approval process 25:46 Vaccine safety monitoring 28:23 Unanswered questions 31:09 Let’s stay tuned for more information 33:12 A fairytale analogy to explain vaccine development difficulties 35:10 We’d love to hear from you! Send your comments/questions to Dr. Pai at covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews and @GoHealio. Disclosures: Pai reports serving on the advisory boards of Abbvie and Gilead Sciences.
Don Dizon, MD, is an innovator in oncology and an expert in social media. In this episode, we discuss the importance of authenticity and how platforms like Tik Tok have helped him engage with patients. Intro :04 About Dizon :17 The interview 1:29 How did you get to where you are from your beginnings? 1:39 How were you able to navigate around the ideology of sub-subspecializing and do all of this exciting and innovative stuff? 5:45 The importance of giving support to faculty members in trying new innovations 10:20 How has your social media life been viewed? How did you become this social media expert and have that be accepted, even lauded by the people you work with? 12:09 How does your social media presence and content provide accessible information to patients while showing a human side? 18:35 How and why did you choose the platforms you engage on? 20:38 How do you come up with content for your TikTok videos? 23:11 What types of things have you done academically that have helped your career and the academic world? 27:55 What are some other pitfalls you’ve noticed with social media? 34:30 If people are interested in doing something off the beaten path … where can they go to get guidance and help? 40:41 Dizon’s one pearl 45:22 How to find Dizon 45:51 Don Dizon, MD, is a professor of medicine at Brown University and is a medical oncologist specializing in the care of women with breast or gynecologic cancers, survivorship, particularly as it pertains to sexual health for men and women with cancer, patient engagement and social media. He also serves as the director of men’s cancers and director of hematology/oncology clinics at Lifespan Cancer Institute in Rhode Island. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Dr. Dizon can be reached on Twitter, Instagram and TikTok at @drdonsdizon. Follow us on Twitter @HemOncToday @ShikhaJainMD Disclosures: Jain reports she is a paid freelance writer for Lippincott. Healio was unable to confirm relevant financial disclosures for Dizon at the time of posting.
In this episode, Benjamin O. Anderson, MD, FACS, creator and chair of The Breast Health Global Initiative at Fred Hutchinson Cancer Research Center and Consultant for Cancer Control to the WHO, shares how his passion for patient care dovetailed into a career in global oncology. Intro :14 About Anderson :20 The interview 2:16 How did you end up in breast cancer care and how did it evolve into global oncology? 2:27 How do you utilize these criteria and protocols and tailor it to each of the countries that come with their own challenges? 11:39 Jain on the importance of global medicine 16:39 Where have you found that implementation of this has been most successful so far? 22:44 Have you seen these protocols used for treating other cancers? 25:50 Have you seen, through your global health work, any cool innovations that have come out of unique situations? 30:57 Going to all these different institutes in different countries, have you found anything that you thought was really amazing and that should be brought stateside? 37:10 Anecdote on the need to find better ways to documentation for billing and its relation to physician burnout 42:10 Jain anecdote on the need for a healthy balance to reduce risk for burnout 45:30 Anecdote on the importance of physicians taking on leadership/government roles 49:20 Have you seen a major change in health care delivery or global oncology navigating through the pandemic? 52:40 Anderson’s one pearl 56:40 How to find Anderson 57:00 Benjamin O. Anderson, MD, FACS, is professor of surgery and global health medicine at the University of Washington, chair and director of The Breast Health Global Initiative at Fred Hutchinson Cancer Research Center, and consultant for cancer control to the WHO. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Dr. Anderson can be reached at bhgi.org. Follow us on Twitter @HemOncToday @ShikhaJainMD Disclosures: Jain reports she is a paid freelance writer for Lippincott. Healio was unable to confirm Anderson’s relevant financial disclosures at the time of posting.
Research and data on potential treatment modalities continue to emerge at a rapid pace. This episode explores the IDSA and NIH guidelines for the treatment and management of COVID-19, as well as available evidence on antivirals, glucocorticoids and antibodies. Intro :08 Recap on spectrum of disease 1:53 Treatment goals: 3 broad approaches 4:07 Disease pathogenesis 5:45 Remdesivir 7:58 Dexamethasone 17:18 Convalescent plasma 34:26 Words from JFK 40:20 We’d love to hear from you! Send your comments/questions to Dr. Pai at covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews and @GoHealio. Disclosures: Pai reports serving on the advisory boards of Abbvie and Gilead Sciences.
TOPIC: The New Normal in Medical Media LENGTH: 28:12PANELISTS: Matthew Holland, John C. Carter, Joan-Marie StiglichHOST: Jason E. CarrisSeason Two of the AMM Conversation, the official podcast of the Association of Medical Media, explores the "new normal" in medical media. In this episode, we are joined by a trio of medical publishing experts discussing how the industry is coping, adapting, and excelling during the Covid-19 pandemic. Our panelists today are from Healio and its parent company, The Wyanoke Group: John C. Carter is Chief Operating Officer of The Wyanoke Group. Healio, Healio Strategic Solutions, Healio Live and SLACK Incorporated are wholly owned subsidiaries of The Wyanoke Group. John has been with the company since 1982.Joan-Marie Stiglich is Chief Content Officer at Healio and a 25-year veteran of medical publishing. She has spent the duration of her career at the company.Matthew Holland is Chief Commercial Officer of Healio Strategic Solutions, where he is responsible for all print, digital and custom sales operations.Resources:Find additional medical media resources via AMM's Knowledge Exchange Center.Next: Ep. 2 features further conversation about the new normal in medical media with Denis Conlon, Sumner Mering, and Alejandro Alvarez from Elsevier's Global Commercial Sales and Marketing Group. Contact us: AMM Conversation is the official podcast of the Association of Medical Media. Send questions and comments about this podcast series to jcarris525@gmail.com.
Welcome to AMM Conversation, the official podcast of the Association of Medical Media (ammonline.org). Season Two explores the "new normal" in medical media, as the industry copes, adapts, and excels in the face of the global health crisis. Guests this season include Healio's Matt Holland and JoanMarie Stiglich, Elsevier's Denis Conlon and Alejandro Alvarez, and Kantar's David Emery. Listen weekly via Apple Podcasts, Spotify, Google Podcasts, Stitcher, or wherever you enjoy podcasts.
As the country prepares to reopen, rapid and effective testing remains “the need of the hour.” In this episode, Dr. Pai discusses diagnostic testing for COVID-19, including which populations to prioritize for testing, available modalities and new options. Overview of symptoms 1:05 A look at testing modalities 3:34 Saliva samples for COVID-19 11:19 Antibody testing 13:03 Antigen testing 21:48 Nothing can replace clinical judgment 24:20 We’d love to hear from you! Send your comments/questions to covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews and @GoHealio. Disclosures: Pai reports serving on the advisory boards of Abbvie and Gilead Sciences.
In this episode, Dr. Pai answers questions specific to HIV in the context of COVID-19, including parallels between the two pandemics, repercussions of COVID-19 on patients with HIV and guidance for handling potential changes to antiretroviral regimens. Questions: From Peter Chin-Hong, MD, at the University of California, San Francisco: "What are the parallels between the HIV and COVID-19 epidemic?" "What lessons can we learn from the early response to HIV that can inform how we approach COVID-19?" "Are HIV patients with COVID-19 doing worse? What information do we have?" "What repercussions of COVID-19 will HIV patients have (mental illness, etc.)?" From Jennifer Ross, PharmD, at the University of Iowa College of Pharmacy: "Many antiretroviral agents (e.g., l lopinavir/ritonavir, boosted darunavir), are being evaluated in clinical trials or are prescribed for off-label use for the treatment or prevention of COVID-19. What additional considerations should be made when proposing a change in a patient’s antiretroviral regimen in the midst of COVID-19?" We’d love to hear from you! Send your comments/questions to covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews and @GoHealio. Disclosures: Pai reports serving on the advisory boards of Abbvie and Gilead Sciences.
This episode features questions regarding the use of masks, the use of steroids, universal PPE, antibody testing, convalescent plasma, COVID-19 in pets and whether hydroxychloroquine has any effect on the cytokine storm. Questions: From Gail D. Deyle, DSc, of the Brooke Army Medical Center, in San Antonio, Texas: “The information available to the general public has ranged from masks do very little to help reduce the spread of the virus, to statements that if 80% of the population wore a mask, most transmission would be stopped. Consistent with current evidence, and distinct from fears of the general public competing with healthcare providers to purchase masks, what benefit do homemade and other masks provide? Is your family wearing masks?” From Mike Putman, MD, of Feinberg School of Medicine at Northwestern University: “I'd love to hear the panel talk about steroids.” From Adam Cheifetz, MD, of Beth Israel Deaconess Medical Center: “How contagious are carriers prior to being symptomatic and for how long after diagnosis are you still contagious? “When will we see a serology test to determine if someone, ourselves included, have already had COVID-19?” From Masoud Sakhaei, MD, of Baptist Health in Jacksonville, FL: “Most likely, COVID-19 will be with us. Until we have a vaccine or cure, we do have to find a balance between livable society and avoidance of infection and fatality. We need a better universal PPE to be cheap and abundant for everybody to be able to go back to work and be protected.” “We need universal screening to collect antibodies from recovered individuals in case somebody got sick. I’d like the panel’s opinion on this.” From Scott Harris, MD, a retired cardiologist previously in private practice in Texas: “Does the activity of hydroxychloroquine in reducing cytokine levels in vitro have a possible beneficial effect in blunting the cytokine storm?” From Marcia Miller-Hjelle, PhD, of the University of Illinois College of Medicine at Peoria: “Why have veterinarians not been brought into the mix of providing information and studies, such as are cats and dogs carriers of COVID-19? Hopefully, someone is testing this.” From Stephen Hanauer, MD, of Northwestern University: “We are planning a meeting in December, but faculty are concerned about recycling of the virus. Are there any predictions on what will happen when we return to socializing and winter returns?” We’d love to hear from you! Send your comments/questions to mailto:covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews and @GoHealio. Disclosures: Pai reports serving on the advisory boards of Abbvie and Gilead Sciences.
This episode focuses on diabetes and COVID-19. Questions are answered regarding the risk for COVID-19 among patients with diabetes, medication concerns in those who test positive for the virus, and the importance of self-monitoring of glucose levels among patients with type 1 and type 2 diabetes. Questions: From Shelley Johns, PsyD, HSPP, ABPP, from Indiana University Melvin and Bren Simon Comprehensive Cancer Center: "Do individuals with diabetes have any added risk of contracting coronavirus, and does this risk vary by their recent blood glucose control?" From Rachel Pessah-Pollack, MD, from NYU Langone Health: "Are there any medications that should be stopped if a patient has diabetes and COVID-19?" "Are glucose levels higher if a patient has diabetes and COVID-19?" "Is there any additional monitoring that should be done if patients have type 1 diabetes and COVID-19?" We’d love to hear from you! Send your comments/questions to mailto:covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews and @GoHealio. Disclosures: Pai reports serving on the advisory boards of Abbvie and Gilead Sciences.
As the enormity of the COVID-19 pandemic sinks in and as we feel its impact across the globe, join us as we discuss mitigation, solutions and new discoveries and approaches to help you better prepare to serve your patients across all specialties. In this episode, we focus on immunocompromised patients. Questions: From David Duong, MD, from the Harvard Primary Care Center: Should the safe default be to recommend testing for COVID-19 if they have any URI +/- diarrheal symptoms since the implications could be huge for them? Or is there additional screening that we should do before recommending to test? What do you do if tests are extremely limited/not available? From Derek Raghavan, MD, PhD, from the Levine Cancer Institute: How do you balance long-term outcomes from dose-intense regimens vs. the immediate threats of myelosuppression with COVID-19 hovering around? What is your view of broad-based antiviral therapies in association with cancer treatments as a protective adjunct, given the absence of hard data? Are you routinely prescribing chloroquine and similar compounds and why/why not? From John Sweetenham, MD, from the University of Texas Southwestern Medical Center: One question comes to mind immediately: We are applying a symptom screen for our patients on entry to the cancer center and are now likely to add a temperature screen to that process. I would love to know what threshold temperature we should consider a positive screen in immunocompromised patients. It’s a simple question but of huge practical importance and I can’t find a good answer anywhere. From Shelley Johns, PsyD, HSPP, ABPP, from Indiana University Melvin and Bren Simon Comprehensive Cancer Center: Does a history of cancer -- and treatment with chemotherapy, radiation therapy, endocrine therapy and/or any targeted therapies -- raise a person’s risk of contracting coronavirus or their health complications from it? From Deepak Bhatt, MD, from Brigham and Women's Hospital: How should we deal with a health care worker who gets a needlestick from a COVID-positive patient? From Carl Pepine, MD, from the University of Florida Health: The most immunocompromised patients that we see in cardiology are those who have had heart transplantation for heart failure. What are the recommendations for patients who have had a heart transplant after they leave the hospital? We’d love to hear from you! Send your comments/questions to mailto:covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews and @GoHealio. Disclosures: Pai reports serving on the advisory boards of Abbvie and Gilead Sciences.
Try your hand at this medical mystery, which is followed by some didactics on a fascinating disease which will hopefully make sense of this inscrutable title. Brought to you by GSK. Consider the long-term impact of disease activity, flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com Intro :22 What to expect in each episode :30 The case: A 75-year-old man with Sjogren’s and MALT lymphoma presents with recurrent cerebral infarcts of multiple territories 1:10 Rheumatology is consulted 6:11 Decreased sensation in toes occurs between strokes 7:14 What’s going on with this patient? 8:36 What additional labs can we perform? 9:36 We spin the urine 11:10 What kind of vasculitis are Sjogren’s and lymphoma associated with? 12:22 C3 and C4 had already been performed 13:00 An overall picture of this patient 13:54 What about the strokes? 14:19 Should we do more imaging? 15:57 At this point we can make a clinical decision 16:33 Why make a decision so quickly vs. waiting for biopsy? 18:18 Two things you must check before moving forward with a cryoglobulinemic vasculitis 19:46 Spoiler alert: The patient is doing really well 20:16 Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com. What is cryoglobulinemic vasculitis? 21:00 What are these immunoglobulins? There are three types of cryoglobulins 22:55 Usually driven by another identifiable disease 25:18 What is making these immunoglobulins? 26:49 We don’t know why these immunoglobulins behave this way 27:18 How do you explain the kidneys? 28:28 What’s occurring at the tissue level? 29:35 How does type 1 present? 30:50 Type 2 and type 3 31:12 What other organ systems are involved? 33:11 I hope you enjoyed this patient presentation 36:00 What we’ll discuss in episodes 2 and 3 36:05 Thanks for listening 38:03 **Coming soon from Healio, Unmasking COVID-19, a podcast hosted by Gitanjali Pai, MD, infectious disease physician at Memorial Hospital and Physicians’ Clinic in Stilwell, Oklahoma. In this timely new show, Dr. Pai will explore COVID-19’s impact on vulnerable patient populations by answering questions from experts in various medical fields, including oncology, endocrinology and rheumatology. To submit your question for Dr. Pai, email covid19podcast@healio.com.** We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum @LCalabreseDO @CCalabreseDO Disclosure: Brown reports no relevant financial disclosures. References: Fuentes A, et al. Current Rheumatology Reports. 2019;21:60. Silva F, et al. J Autoimmun. 2019;105:102313.
Healio's Matt Holland and Andrea Gaymon join MM&M editor-in-chief Steve Madden for an engrossing conversation about innovating with content, giving clients exactly what they want and the benefits of working for family-owned companies.
“Acute rheumatic fever is proceeded by an infection with Group A strep” is a mantra that all health care workers know. This episode digs through the history of how we came to understand this fact, as well as how our understanding of the pathophysiology and treatment of rheumatic fever developed. Intro :10 Why I made this episode :30 Outline of this episode 1:55 Rheumatic fever was really bad 3:10 The early 1700s 4:10 A big leap 6:15 The Jones criteria 11:07 History of the bacteriology 14:23 The heroic ASO titre 20:51 Rheuminations is powered by Healio 21:40 Another breakthrough: penicillin 21:51 Not all group A strep is the same 25:06 The decline of rheumatic fever 25:56 What about the host? 29:30 The joints 38:56 Summary 40:28 Never appreciated how bad rheumatic fever was 42:18 We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum References: A History of Medical Bacteriology and Immunology, First Edition, Butterworth-Heinemann, Oxford, 1970. Aspinall GO, et al. Infect Immun. 1994;62:2122-2125. Carapetis JR, et al. Nat Rev Dis Primer. 2016;doi:10.1038/nrdp.2015.84. Cox CJ, et al. J Immunol. 2013;doi:10.4049/jimmunol.1102592. Engel ME, et al. PLoS One. 2011;6:e25326. FW Denny, et al. JAMA. 1950;143:151-153. Gray LA, et al. J Infect Dis. 2017;216:1460-1470. Kaplan MH, et al. Lancet. 1962;1:706-710. Karthikeyan G, Guilherme L. Lancet. 2018;392:161-174. Khandke KM, et al. J Exp Med. 1987;doi:10.1084/jem.166.1.151. Paul O, et al. Clin Cardiol. 1990;13:367-369. Quinn A, et al. Infect Immun. 2001;69:4072-4078. Robertson KA, et al. BMC Cardiovasc Disord. 2005;5:11. Rojas Manuel, et al. J Autoimmun; 2018;95:100-123. Tandon R, et al. Nat Rev Cardiol. 2013;10:171-177.
This ripping yarn delves into the history of tumor necrosis factor in relation to rheumatoid arthritis with emphasis on the original studies that set the stage for the use of TNF inhibition in RA. Intro :11 What we’ll cover here :16 Recap of Part 1 1:25 What I discovered when doing this episode 1:22 What this episode won’t address 2:40 Let the tale begin 3:12 A look at matrix metalloproteinases 3:32 A breakthrough in understanding RA 6:28 Two key players: Dr. Mark Feldman and Dr. Ravinder Maini 6:53 The first cytokine research conducted in RA: IL-1 8:00 The next cytokine: Tumor necrosis factor 11:16 What do we know about cytokine production within the joint? 14:33 IL-6 and TGF-beta 19:16 A bit about IL-10 23:57 *Visit Healio.com/rheum for daily news and updates* How do we choose which cytokines to block to make improvements in RA? 25:16 What about in vivo data? 29:45 The history of infliximab 34:00 Infliximab is approved for RA treatment 45:13 TNF in RA: from bedside, to bench then back to bedside 46:06 It’s important to recognize the researchers who discovered these pathways 46:18 Remember the scientists next time you prescribe a TNF inhibitor 47:05 Read the latest news and commentary on Healio.com/rheumatology and Follow us on Twitter @HealioRheum and @HRheuminations for updates 47:34 We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum References: Brennan FM, et al. J Autoimmun. 1989;2 Suppl:177-186. Brennan FM, et al. Lancet. 1989;2:244-247. Butler MD, et al. Eur Cytokine Netw. 1995;6:225-230. Chu CQ, et al. Arthritis Rheum. 1991;34:1125-1132. Dayer JM, et al. J Exp Med. 1985;162:2163-2168. Di Giovine FS, et al. Ann Rheum Dis. 1988;47:768-772. Feldmann, M. Nat Rev Immunol. 2002;2:364-371. Feldmann M, Maini SR. Immunol Rev. 2008;223:7-19. Fontana A, et al. Rheumatol Int. 1982;2:49-53. Haworth C, et al. Eur J Immunol. 1991;21:2575-9. Houssiau FA, et al. Arthritis Rheum. 1988;31:784-8. Keffer J, et al. EMBO J. 1991;10:4025-4031. Kulkarni AB, Karlsson S. Am J Pathol. 1993;143:3-9. Kuruvilla AP, et al. PNAS. 1991;88:2918-2921. Maini RN, et al. Arthritis Rheum. 1998;41:1552-1563. Malaviya AN, Mehra NK. Indian J Med Res. 2018;148:263–278. McInnes IB, Schett G. Nat Rev Immunol. 2007;7:429-442. Mitchison NA, Medawar PB. Proc R Soc Lond [Biol]. 1964;https://doi.org/10.1098/rspb.1964.0093. Pettipher ER, et al. Proc Natl Acad Sci U S A. 1986;83:8749-8753. The Beautiful Cure: The Revolution in Immunology and What It Means for Your Health, University of Chicago Press, Chicago, 2018. Williams RO, et al. Proc Natl Acad Sci U S A. 1992;89:9784-9788. Xu WD, et al. J Clin Invest. 1989;83:876-882.
On Sunday's show I look at the recent news from Rockland County, New York where the County Executive, Ed Day declared a county wide State of Emergency, which effectively banned all unvaccinated people 18 years and younger from entering public places for 30 days or until they get vaccinated. I also looked at the legal implications referring to a Healio interview with vaccine law expert, Brian Dean Abramson. Then there is anti-vaxxer, Robert F Kennedy Jr up to his typical shenanigans on Twitter trying to blame rises in depression and anxiety on the Gardasil vaccine. Do you have a penicillin allergy? Researchers at McMaster University say that you probably don't. In the second half, I play a portion of an interview I had with public health expert, Glenn Laverack, PhD about health promotion and outbreaks.
Richard Furie, MD, is chief, division of rheumatology, at Northwell Health, and professor of medicine at Hofstra/Northwell School of Medicine. Join us in this ACR interview, as we discuss the story of interferon, lupus therapeutics — including B cell depletion — and the future of lupus research and treatments. Intro :10 Background on Dr. Furie :16 The interview :56 What advancements in the pathophysiology of lupus are you most excited about? 1:10 The interferon story 1:23 The interferon story is not finished yet 7:18 Dendritic cells in lupus patients 7:41 What is “interferon signature?” 8:07 Do we see different clinical phenotype in patients with high interferon signature? 9:38 What’s your opinion on the role of B cells? 10:07 Any other pathophysiology mechanisms being used to target B cells? 13:15 Are we stretched thin in terms of number of lupus patients in trials? 15:21 How would designating lupus as an orphan disease change the way it’s investigated? 16:40 What is your main concern regarding study design? 17:37 Looking 10 years ahead, do you think what we call “lupus” will still be referred to as such, or will it be decompartmentalized into different diseases? 21:26 What’s the expense of cytokine profiling? 22:40 What excites you the most about the future of lupus research? 23:21 Thank you, Dr. Furie 24:41 Recap 24:43 Shout out to the 7th Annual Basic and Clinical Immunology for the Busy Clinician: What is New and Hot in Immunology bootcamp in Scottsdale, AZ, Feb. 15-16, 2019 25:31 We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. And be sure to follow us on Twitter @AdamJBrownMD and @HealioRheum. This information is brought to you by Healio and is not sponsored by, nor a part of, the American College of Rheumatology.
John J. O’Shea, MD, is scientific director of the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, and chief of their Molecular Immunology and Inflammation Branch. In this ACR interview, he joins me to talk about the JAK/STAT pathway, what we’ve learned from mouse models, current FDA-approved JAK inhibitors and the future of this exciting field. Intro :10 Background on Dr. O’Shea :45 The interview 2:37 How did you start looking into the JAK/STAT pathway? 3:16 What should a clinician understand about this pathway? 5:22 What do these cytokines have in common? 6:37 What have we learned from mouse models? 8:48 GWAS studies in JAK/STAT 11:49 Can we quantify how much a certain cytokine may be using this pathway? 12:39 Can you explain suppressor of cytokine signaling, aka SOCS? 14:15 What do we know about how these different cytokines can have individual signaling controls? 16:40 An explanation of phenocopy 18:01 What evidence do we have that JAK may circumvent STAT, and vice versa? 18:41 An overview of FDA-approved JAK inhibitors and the pipeline 20:52 What excites you the most about the future of this field? 23:26 In a state of wonder over success of biologics 25:50 Thank you, Dr. O’Shea 27:20 Recap 27:30 We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. And be sure to follow us on Twitter @AdamJBrownMD and @HealioRheum. This information is brought to you by Healio and is not sponsored by, nor a part of, the American College of Rheumatology.
In this ACR interview, the walking encyclopedia of medical history, Eric L. Matteson, MD, of The Mayo Clinic, sits down with me to discuss what excites him about medical history and then takes a deep dive into the history of vasculitis! Intro :10 Background on Dr. Matteson :28 The interview 2:00 How did you get into history? Why does it mean so much to you? 2:19 Can you tell us about the archives at Mayo Clinic? 6:49 An appreciation of present time and how we take some medications for granted 7:55 Brief history of vasculitis 9:23 Kussmaul and the first failed ophthalmoscope 14:20 Kussmaul’s second failure: gastroscope 15:43 When did we get to the small vessel vasculitis/glomerulonephritis description? 17:25 The discovery of Wegener 20:44 Wegener was not the first to describe granulomatosis with polyangiitis, and the folly of naming diseases for individuals 23:24 Thank you, Dr. Matteson 24:57 Recap 25:05 We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. This information is brought to you by Healio and is not sponsored by, nor a part of, the American College of Rheumatology.
Martin J. Blaser, MD, is director of the Human Microbiome Program at NYU and author of the book, Missing Microbes. He sat down and spoke with us about how the microbiome plays a role in disease pathogenesis, including autoimmunity, and he also answered the question of whether all of our patients should be on probiotics! Intro :11 Background on Dr. Blaser :35 The interview 1:20 What is the microbiome? 1:25 How unique are individual microbiomes? 1:49 How does an individual’s microbiome change over time? 2:13 Microbial diversity in different populations 3:12 What’s your concern with the loss of microbiome diversity? 4:20 A bit on Blaser’s research on obesity and antibiotic use 5:21 Is the timing of antibiotic administration important, in terms of the side effects it can produce? 6:43 Worldwide antibiotic prescribing rates 7:54 The microbiome and autoimmunity 9:02 The microbiome and type 1 diabetes, IBD 10:45 Research with IL-17 12:23 Microbiota transplants 13:09 For how long is the microbiome perturbed after giving antibiotics? 13:57 Diet and microbiome findings 14:54 Probiotics, prebiotics and symbiotics 15:33 In 10 years, how will people be investigating/manipulating the microbiome? 18:18 Have we shown with research that introducing certain types of bacteria can be sustainable in the gut? 19:47 Thank you, Dr. Blaser 20:26 Summary 20:33 We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. This information is brought to you by Healio and is not sponsored by, nor a part of, the American College of Rheumatology.
In this inaugural episode, Darrell White, MD, gives the background of how he came to be Healio.com/OSN’s first podcaster, starting out from blogging, to The Dry Eye columnist to podcaster. While becoming known as Healio.com/OSN’s dry eye disease expert, he delves into his background as an anterior segment ophthalmologist with a cross-interest in business and the ongoing arc of his career. Disclaimer :09 Introduction: “You have been reading my blog posts, haven’t you?” 1:00 It’s great you’re a dry eye expert, but do you still operate? 2:22 Who am I and why should you care what I think? 2:51 The arc of an ophthalmology career 3:23 Starting out in private practice 3:57 How did I get into ophthalmology? 4:45 Thinking about the intersection between health care and commerce 9:10 Finding your voice by taking care of patients 10:40 Lessons learned starting a private practice during an economic recession 11:59 Demographics are on the side of the ophthalmologist 13:25 Making the connection between industry and patient care 14:34 Let’s have a conversation about ideas 14:38
© 2020-2025 Ivy Podcast Discovery LLC
